

**ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography:  
Summary Article: A Report of the American College of Cardiology/American Heart  
Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the  
1997 Guidelines for the Clinical Application of Echocardiography)**

Committee Members, Melvin D. Cheitlin, William F. Armstrong, Gerard P. Aurigemma, George A. Beller, Fredrick Z. Bierman, Jack L. Davis, Pamela S. Douglas, David P. Faxon, Linda D. Gillam, Thomas R. Kimball, William G. Kussmaul, Alan S. Pearlman, John T. Philbrick, Harry Rakowski, Daniel M. Thys, Elliott M. Antman, Sidney C. Smith, Jr, Joseph S. Alpert, Gabriel Gregoratos, Jeffrey L. Anderson, Loren F. Hiratzka, David P. Faxon, Sharon Ann Hunt, Valentin Fuster, Alice K. Jacobs, Raymond J. Gibbons and Richard O. Russell

*Circulation*. 2003;108:1146-1162

doi: 10.1161/01.CIR.0000073597.57414.A9

*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2003 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the  
World Wide Web at:

<http://circ.ahajournals.org/content/108/9/1146>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation* is online at:  
<http://circ.ahajournals.org/subscriptions/>

## ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article

### A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography)

#### Committee Members

Melvin D. Cheitlin, MD, MACC, Chair; William F. Armstrong, MD, FACC, FAHA;  
Gerard P. Aurigemma, MD, FACC, FAHA; George A. Beller, MD, FACC, FAHA;  
Fredrick Z. Bierman, MD, FACC; Jack L. Davis, MD, FACC;  
Pamela S. Douglas, MD, FACC, FAHA, FASE; David P. Faxon, MD, FACC, FAHA;  
Linda D. Gillam, MD, FACC, FAHA; Thomas R. Kimball, MD, FACC;  
William G. Kussmaul, MD, FACC; Alan S. Pearlman, MD, FACC, FAHA, FASE;  
John T. Philbrick, MD, FACP; Harry Rakowski, MD, FACC, FASE;  
Daniel M. Thys, MD, FACC, FAHA

#### Task Force Members

Elliott M. Antman, MD, FACC, FAHA, Chair; Sidney C. Smith, Jr, MD, FACC, FAHA, Vice-Chair;  
Joseph S. Alpert, MD, FACC, FAHA; Gabriel Gregoratos, MD, FACC, FAHA;  
Jeffrey L. Anderson, MD, FACC; Loren F. Hiratzka, MD, FACC, FAHA;  
David P. Faxon, MD, FACC, FAHA; Sharon Ann Hunt, MD, FACC, FAHA;  
Valentin Fuster, MD, PhD, FACC, FAHA; Alice K. Jacobs, MD, FACC, FAHA;  
Raymond J. Gibbons, MD, FACC, FAHA\*†; Richard O. Russell, MD, FACC, FAHA\*

\*Former Task Force Member. †Immediate Past Task Force Chair.

#### I. General Considerations and Scope

The previous guideline for the use of echocardiography was published in March 1997. Since that time, there have been significant advances in the technology of echocardiography

and growth in its clinical use and in the scientific evidence leading to recommendations for its proper use.

Each section has been reviewed and updated in evidence tables, and where appropriate, changes have been made in

This document was approved by the American College of Cardiology Foundation Board of Trustees in May 2003, by the American Heart Association Science Advisory and Coordinating Committee in May 2003, and by the American Society of Echocardiography Board of Directors in May 2003.

The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. The relationship with industry information for the writing committee members is posted on the ACC and AHA World Wide Web sites with the full-length version of the update.

When citing this document, the American College of Cardiology, American Heart Association, and the American Society of Echocardiography request that the following citation format be used: Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines on the Clinical Application of Echocardiography). *Circulation*. 2003;108:1146–1162.

This document and the full text guideline are available on the World Wide Web sites of the American College of Cardiology ([www.acc.org](http://www.acc.org)), the American Heart Association ([www.americanheart.org](http://www.americanheart.org)), and the American Society of Echocardiography ([www.asecho.org](http://www.asecho.org)). To obtain a single copy of this summary article published in the September 3, 2003, issue of the *Journal of the American College of Cardiology*, the September 2, 2003, issue of *Circulation*, or the October, 2003, issue of the *Journal of the American Society of Echocardiography*, call 1-800-253-4636 or write to the American College of Cardiology Foundation, Resource Center, 9111 Old Georgetown Road, Bethesda, MD 20814-1699, and ask for reprint number 71-0263. To purchase additional reprints: up to 999 copies, call 1-800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or e-mail [pubauth@heart.org](mailto:pubauth@heart.org).

(*Circulation*. 2003;108:1146–1162.)

©2003 by the American College of Cardiology Foundation and the American Heart Association, Inc.

*Circulation* is available at <http://www.circulationaha.org>

DOI: 10.1161/01.CIR.0000073597.57414.A9

recommendations. A new section on the use of intraoperative transesophageal echocardiography (TEE) is being added to update the guidelines published by the American Society of Anesthesiologists and the Society of Cardiovascular Anesthesiologists. There are extensive revisions, especially of the sections on ischemic heart disease; congestive heart failure, cardiomyopathy, and assessment of left ventricular (LV) function; and screening and echocardiography in the critically ill. There are new tables of evidence and extensive revisions in the ischemic heart disease evidence tables.

Because of space limitations, only those sections and evidence tables with new recommendations will be printed in this summary article. Where there are minimal changes in a recommendation grouping, such as a change from Class IIa to Class I, only that change will be printed, not the entire set of recommendations. Advances for which the clinical applications are still being investigated, such as the use of myocardial contrast agents and three-dimensional echocardiography, will not be discussed.

The original recommendations of the 1997 guideline are based on a Medline search of the English literature from 1990 to May 1995. The original search yielded more than 3000 references, which the committee reviewed. For this guideline update, literature searching was conducted in Medline, EMBASE, Best Evidence, and the Cochrane Library for English-language meta-analyses and systematic reviews from 1995 through September 2001. Further searching was conducted for new clinical trials on the following topics: echocardiography in adult congenital heart disease, echocardiography for evaluation of chest pain in the emergency department, and intraoperative echocardiography. The new searches yielded more than 1000 references that were reviewed by the writing committee.

This document includes recommendations for the use of echocardiography in both adult and pediatric patients. The pediatric guidelines also include recommendations for fetal echocardiography, an increasingly important field. The guidelines include recommendations for the use of echocardiography in both specific cardiovascular disorders and the evaluation of patients with frequently observed cardiovascular symptoms and signs, common presenting complaints, or findings of dyspnea, chest discomfort, and cardiac murmur. In this way, the guidelines will provide assistance to physicians regarding the use of echocardiographic techniques in the evaluation of such common clinical problems.

The recommendations concerning the use of echocardiography follow the indication classification system (eg, Class I, II, and III) used in other American College of Cardiology/American Heart Association (ACC/AHA) guidelines:

**Class I:** Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.

**Class II:** Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.

**IIa:** Weight of evidence/opinion is in favor of usefulness/efficacy.

**IIb:** Usefulness/efficacy is less well established by evidence/opinion.

**Class III:** Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful.

Evaluation of the clinical utility of a diagnostic test such as echocardiography is far more difficult than assessment of the efficacy of a therapeutic intervention because the diagnostic test can never have the same direct impact on patient survival or recovery. Nevertheless, a series of hierarchical criteria are generally accepted as a scale by which to judge worth.<sup>1-3</sup>

### *Hierarchical Levels of Echocardiography Assessment*

- Technical capacity
- Diagnostic performance
- Impact on diagnostic and prognostic thinking
- Therapeutic impact
- Health-related outcomes

Because there are essentially no randomized trials assessing health outcomes for diagnostic tests, the committee has not ranked the available scientific evidence in an A, B, and C fashion (as in other ACC/AHA documents) but rather has compiled the evidence in tables. The evidence tables have been extensively revised and updated. All recommendations are thus based on either this evidence from observational studies or on the expert consensus of the committee.

The definition of echocardiography used in this document incorporates Doppler analysis, M-mode echocardiography, two-dimensional transthoracic echocardiography (TTE), and, when indicated, TEE. Intravascular ultrasound is not considered but is reviewed in the ACC/AHA Guidelines for Percutaneous Coronary Intervention<sup>1</sup> (available at <http://www.acc.org/clinical/guidelines/percutaneous/dirIndex.htm>) and the Clinical Expert Consensus Document on intravascular ultrasound<sup>2</sup> (available at <http://www.acc.org/clinical/consensus/standards/standard12.htm>). Echocardiography for evaluating the patient with cardiovascular disease for noncardiac surgery is considered in the ACC/AHA Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery.<sup>3</sup> The techniques of three-dimensional echocardiography are still in the developmental stages and are not considered here. New techniques that are still rapidly evolving and improvements that are purely technological in echo-Doppler instrumentation, such as color Doppler imaging and digital echocardiography, are not going to be separately discussed in the clinical recommendations addressed in this document. Tissue Doppler imaging, both pulsed and color, which detects low Doppler shift frequencies of high energy generated by the contracting myocardium and consequent wall motion, are proving very useful in evaluating systolic and diastolic myocardial function. However, these technological advances will also not be separately discussed in the clinical recommendations.<sup>4,5</sup> Echocardiographic-contrast injections designed to assess myocardial perfusion to quantify myocardium at risk and perfusion beds also were not addressed.

These guidelines address recommendations about the frequency with which an echocardiographic study is repeated. If

the frequency with which studies are repeated could be decreased without adversely affecting the quality of care, the economic savings realized would likely be significant. With a noninvasive diagnostic study and no known complications, the potential for repeating the study unnecessarily exists. It is easier to state when a repeat echocardiogram is not needed than when and how often it should be repeated, because no studies in the literature address this question. How often an echocardiogram should be done depends on the individual patient and must be left to the judgment of the physician until evidence-based data addressing this issue are available.

The ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography includes several significant changes in the recommendations and in the supporting narrative portion. In this summary, we list the updated recommendations, as well as commentary on some of the changes. All new or revised language in recommendations appears in boldface type. Only the references supporting the new recommendations are included in this article. The reader is referred to the full-text version of the guidelines posted on the American College of Cardiology ([www.acc.org](http://www.acc.org)), American Heart Association ([www.americanheart.org](http://www.americanheart.org)), and American Society for Echocardiography ([www.asecho.org](http://www.asecho.org)) World Wide Web sites for a more detailed exposition of the rationale for these changes.

## Section II-B. Native Valvular Stenosis

### Recommendations for Echocardiography in Valvular Stenosis

Comment: New references.<sup>6,7</sup>

#### Class IIb

2. **Dobutamine echocardiography for the evaluation of patients with low-gradient aortic stenosis and ventricular dysfunction.**

## Section II-C. Native Valvular Regurgitation

### Recommendations for Echocardiography in Native Valvular Regurgitation

Comment: Literature on valvular effects of anorectic drugs and references to echocardiographic predictors of prognosis after aortic and mitral valve surgery have been added.<sup>6–10</sup>

#### Class I

7. Assessment of the effects of medical therapy on the severity of regurgitation and ventricular compensation and function **when it might change medical management.**
8. **Assessment of valvular morphology and regurgitation in patients with a history of anorectic drug use, or the use of any drug or agent known to be associated with valvular heart disease, who are symptomatic, have cardiac murmurs, or have a technically inadequate auscultatory examination.**

#### Class III

2. **Routine repetition of echocardiography in past users of anorectic drugs with normal studies or known trivial valvular abnormalities.**

## Section II-F. Infective Endocarditis: Native Valves

### Recommendations for Echocardiography in Infective Endocarditis: Native Valves

Comment: The Duke Criteria for the diagnosis of infective endocarditis have been added, as well as the value of TEE in the setting of a negative transthoracic echocardiogram when there is high clinical suspicion or when a prosthetic valve is involved.<sup>11,12</sup>

#### Class I

6. **If TTE is equivocal, TEE evaluation of staphylococcus bacteremia without a known source.**

#### Class IIa

1. Evaluation of **persistent nonstaphylococcus** bacteremia without a known source.\*

#### Class III

1. Evaluation of **transient** fever without evidence of bacteremia **or new murmur.**

\*TEE may **frequently** provide incremental value in addition to information obtained by TTE. The role of TEE in first-line examination awaits further study.

## Section II-G. Prosthetic Valves

### Recommendations for Echocardiography in Valvular Heart Disease and Prosthetic Valves

#### Class I

3. Use of echocardiography (especially TEE) in **guiding the performance of** interventional techniques **and surgery** (eg, balloon valvotomy **and valve repair**) for valvular disease.

## Section IV-A. Acute Ischemic Syndromes

### Recommendations for Echocardiography in the Diagnosis of Acute Myocardial Ischemic Syndromes

Comment: Movement of a recommendation from Class IIa to Class I and minor wording change.

### Recommendations for Echocardiography in Risk Assessment, Prognosis, and Assessment of Therapy in Acute Myocardial Ischemic Syndromes

#### Class I

4. **Assessment of myocardial viability when required to define potential efficacy of revascularization.\***

#### Class IIa

2. Moved to Class I (see above).

#### Class IIb

1. Assessment of **late** prognosis (greater than or equal to 2 years after acute myocardial infarction).

\*Dobutamine stress echocardiography.

## Section IV-B. Chronic Ischemic Heart Disease

### Recommendations for Echocardiography in Diagnosis and Prognosis of Chronic Ischemic Heart Disease

Comment: There are new sections on stress echocardiography in the detection of coronary disease in the transplanted heart and stress echocardiography in the detection of coronary disease in women. There is one new Class I recommendation and three new Class IIa recommendations. Recommendations have been renumbered for clarity.

#### Class I

2. Exercise echocardiography for diagnosis of myocardial ischemia in selected patients (those for whom ECG assessment is less reliable because of digoxin use, LVH or with more than 1 mm ST depression at rest on the baseline ECG, those with pre-excitation [Wolff-Parkinson-White] syndrome, complete left bundle-branch block) with an intermediate pretest likelihood of CAD.

#### Class IIa

1. Prognosis of myocardial ischemia in selected patients (those in whom ECG assessment is less reliable) with the following ECG abnormalities: pre-excitation (Wolff-Parkinson-White) syndrome, electronically paced ventricular rhythm, more than 1 mm of ST depression at rest, complete left bundle-branch block.\*
2. Detection of coronary arteriopathy in patients who have undergone cardiac transplantation.†
3. Detection of myocardial ischemia in women with a low or intermediate pretest likelihood of CAD.\*

#### Class IIb

1. Moved to Class IIa.

\*Exercise or pharmacological stress echocardiogram.

†Dobutamine stress echocardiogram.

### Recommendations for Echocardiography in Assessment of Interventions in Chronic Ischemic Heart Disease

One new Class IIa recommendation has been added.

#### Class IIa

1. Assessment of LV function in patients with previous myocardial infarction when needed to guide possible implantation of implantable cardioverter-defibrillator (ICD) in patients with known or suspected LV dysfunction.

Tables 1 through 6 are new tables that relate to CAD.

## Section V-B. Regional LV Function

### Recommendations for Echocardiography in Patients With Dyspnea, Edema, or Cardiomyopathy

#### Class I

1. Dyspnea with clinical signs of heart disease.

#### Class IIb

1. Re-evaluation of patients with established cardiomyopathy when there is no change in clinical status **but when the results might change management.**

#### Class III

2. Routine re-evaluation in clinically stable patients in whom no change in management is contemplated **and for whom the results would not change management.**

## Section IX. Pulmonary Disease

### Recommendations for Echocardiography in Pulmonary and Pulmonary Vascular Disease

Comment: One recommendation was moved from Class I to Class IIa. Class IIa recommendations have been renumbered for clarity. Evidence was added concerning the diagnosis of severe pulmonary embolism by echocardiography.<sup>122</sup>

#### Class I

2. Moved to Class IIa (see below).

#### Class IIa

1. Pulmonary emboli and suspected clots in the right atrium or ventricle or main pulmonary artery branches.\*

\*TEE is indicated when TTE studies are not diagnostic.

## Section XII. Arrhythmias and Palpitations

### Recommendations for Echocardiography in Patients With Arrhythmias and Palpitations

Comment: An additional Class IIb recommendation was made concerning the use of echocardiography in the Maze procedure.<sup>123–129</sup>

#### Class IIa

2. TEE or intracardiac ultrasound guidance of radiofrequency ablative procedures.

#### Class IIb

3. Postoperative evaluation of patients undergoing the Maze procedure to monitor atrial function.

### Recommendations for Echocardiography Before Cardioversion

#### Class IIb

2. Patients with mitral valve disease or hypertrophic cardiomyopathy who have been on long-term anticoagulation at therapeutic levels before cardioversion **unless there are other reasons for anticoagulation (eg, prior embolus or known thrombus on previous TEE).**\*

\*TEE only.

**TABLE 1. Evaluation of Myocardial Viability With DSE in Patients With Chronic CAD and Impaired Systolic LV Function to Detect Hibernating Myocardium**

| First Author, Year    | Ref. | Stress | Total Patients | Criteria       | Sensitivity % | Specificity % | PPV % | NPV % | Accuracy % |
|-----------------------|------|--------|----------------|----------------|---------------|---------------|-------|-------|------------|
| Marzullo, 1993        | 13   | LD-DSE | 14             | Imp. WM*       | 82            | 92            | 95    | 73    | 85         |
| Cigarroa, 1993        | 14   | LD-DSE | 25             | Imp. WM†       | 82            | 86            | 82    | 86    | 84         |
| Alfieri, 1993         | 15   | LD-DSE | 14             | Imp. WM*       | 91            | 78            | 92    | 76    | 88         |
| La Canna, 1994        | 16   | LD-DSE | 33             | Imp. WM*       | 87            | 82            | 90    | 77    | 85         |
| Charney, 1994         | 17   | LD-DSE | 17             | Imp. WM*       | 71            | 93            | 92    | 74    | 81         |
| Afridi, 1995          | 18   | DSE    | 20             | Imp. WM†       | 80            | 90            | 89    | 82    | 85         |
| Perrone-Filardi, 1995 | 19   | LD-DSE | 18             | Imp. WM*       | 88            | 87            | 91    | 82    | 87         |
| Senior, 1995          | 20   | LD-DSE | 22             | Imp. WM*       | 87            | 82            | 92    | 73    | 86         |
| Haque, 1995           | 21   | LD-DSE | 26             | Imp. WM*       | 94            | 80            | 94    | 80    | 91         |
| Arnese, 1995          | 22   | LD-DSE | 38             | Imp. WM*       | 74            | 96            | 85    | 93    | 91         |
| deFilippi, 1995       | 23   | LD-DSE | 23             | Imp. WM*       | 97            | 75            | 87    | 93    | 89         |
| Iliceto, 1996         | 24   | LD-DSE | 16             | Imp. WM*       | 71            | 88            | 73    | 87    | 83         |
| Varga, 1996           | 25   | LD-DSE | 19             | Imp. WM*       | 74            | 94            | 93    | 78    | 84         |
| Baer, 1996            | 26   | LD-DSE | 42             | Imp. WM†       | 92            | 88            | 92    | 88    | 90         |
| Vanoverschelde, 1996  | 27   | LD-DSE | 73             | Imp. WM†       | 88            | 77            | 84    | 82    | 84         |
| Gerber, 1996          | 28   | LD-DSE | 39             | Imp. WM*       | 71            | 87            | 89    | 65    | 77         |
| Bax, 1996             | 29   | LD-DSE | 17             | Imp. WM*       | 85            | 63            | 49    | 91    | 70         |
| Perrone-Filardi, 1996 | 30   | LD-DSE | 18             | Imp. WM*       | 79            | 83            | 92    | 65    | 81         |
| Qureshi, 1997         | 31   | LD-DSE | 34             | Imp. WM*       | 86            | 68            | 51    | 92    | 73         |
| Qureshi, 1997         | 31   | DSE    | 34             | Biphasic resp* | 74            | 89            | 72    | 89    | 85         |
| Nagueh, 1997          | 32   | LD-DSE | 18             | Imp. WM*       | 91            | 66            | 61    | 93    | 75         |
| Nagueh, 1997          | 32   | DSE    | 18             | Biphasic resp* | 68            | 83            | 70    | 82    | 77         |
| Furukawa, 1997        | 33   | LD-DSE | 53             | Imp. WM*       | 79            | 72            | 76    | 75    | 76         |
| Cornel, 1997          | 34   | LD-DSE | 30             | Imp. WM*       | 89            | 82            | 74    | 93    | 85         |

DSE indicates dobutamine stress echocardiography (dobutamine infused at both low and high doses); CAD, coronary artery disease; LV, left ventricular; Ref. reference number; Stress, DSE protocol used for pharmacological stress; Total Patients, number of patients with chronic CAD and LV dysfunction in whom DSE studies were analyzed; Criteria, findings on DSE considered as a "positive" indicator of viability; PPV, positive predictive value (likelihood that presence of viability by DSE is indicative of subsequent functional recovery after revascularization); NPV, negative predictive value (likelihood that absence of viability by DSE is indicative of lack of functional recovery after revascularization); LD-DSE, low dose DSE; Imp. WM, improved wall motion during dobutamine stress in a previously asynergic segment; and Biphasic resp, biphasic response, defined as improvement in wall motion during LD-DSE followed by worsening at high dose.

In these patients, percutaneous or surgical revascularization was performed after DSE testing. Those patients demonstrating improved wall motion on follow-up resting transthoracic echocardiography were considered to have had impaired LV function due to hibernating myocardium, whereas those demonstrating no improvement despite revascularization were considered to have had impaired LV function due to necrotic myocardium.

\*Wall motion analyzed by segment; †wall motion analyzed by patient.

### Class III

- Patients who have been on long-term anticoagulation at therapeutic levels and who do not have mitral valve disease or hypertrophic cardiomyopathy before cardioversion **unless there are other reasons for anticoagulation (eg, prior embolus or known thrombus on previous TEE).**\*

\*TEE only.

## Section XIIa. Screening

### Recommendations for Echocardiography to Screen for the Presence of Cardiovascular Disease

Comment: A section has been added on the molecular genetics work that has identified a familial basis for many forms of cardiomyopathy, including dilated congestive car-

diomyopathy, hypertrophic cardiomyopathy, and right ventricular (RV) dysplasia. A possible genetic basis for these cardiomyopathies supports echocardiographic screening of first-degree relatives.<sup>130–138</sup>

### Class I

- First-degree relatives (parents, siblings, children) of patients with unexplained dilated cardiomyopathy in whom no etiology has been identified.**

### Class III

- Routine screening echocardiogram for participation in competitive sports in patients with normal cardiovascular history, ECG, and examination.**

**TABLE 2. Prognostic Value of Stress Echocardiography in Various Patient Populations\***

| First Author, Year             | Reference | Stress      | Total Pts | Avg F/U, mo | Events     | Annualized Event Rate, % |             |        |
|--------------------------------|-----------|-------------|-----------|-------------|------------|--------------------------|-------------|--------|
|                                |           |             |           |             |            | Ischemia                 | No Ischemia | Normal |
| Chronic ischemic heart disease |           |             |           |             |            |                          |             |        |
| Picano, 1989                   | 35        | DIP†        | 539       | 36          | D, MI      | 2.3                      | 0.7         | ...    |
| Sawada, 1990                   | 36        | NL TME      | 148       | 28.4        | D, MI      | ...                      | ...         | 0.6    |
| Mazeika, 1993                  | 37        | DSE†        | 51        | 24          | D, MI, UA  | 16                       | 3.8         | ...    |
| Krivokapich, 1993              | 38        | TME†        | 360       | ≈12         | D, MI      | 10.8                     | 3.1         | ...    |
| Afridi, 1994                   | 39        | DSE†        | 77        | 10          | D, MI      | 48                       | 8.9         | 3      |
| Poldermans, 1994               | 40        | DSE†        | 430       | 17          | D, MI      | 6.6                      | 3.4         | ...    |
| Coletta, 1995                  | 41        | DIP†        | 268       | 16          | D, MI      | 17.9                     | 1.4         | ...    |
| Kamaran, 1995                  | 42        | DSE†        | 210       | 8           | D, MI      | 69                       | 1           | ...    |
| Williams, 1996                 | 43        | DSE†        | 108       | 16          | D, MI, Re  | 32.6                     | 7.3         | ...    |
| Anthopoulos, 1996              | 44        | DSE†        | 120       | 14          | D, MI      | 13.6                     | 0           | ...    |
| Marcovitz, 1996                | 45        | DSE†        | 291       | 15          | D, MI      | 12.8                     | 8.2         | 1.1    |
| Heupler, 1997                  | 46        | TME†        | 508w      | 41          | D, MI, Re  | 9.2                      | 1.3         | ...    |
| McCully, 1998                  | 47        | NL TME      | 1325      | 23          | D, MI      | ...                      | ...         | 0.5    |
| Chuah, 1998                    | 48        | DSE‡        | 860       | 24          | D, MI      | 6.9                      | 6.3         | 1.9    |
| Cortigiani, 1998               | 49        | DSE or DIP† | 456w      | 32          | D, MI      | 2.9                      | 0.3         | ...    |
| Davar, 1999                    | 50        | NL DSE      | 72w       | 13          | D, MI      | ...                      | ...         | 0      |
| After cardiac transplantation  |           |             |           |             |            |                          |             |        |
| Ciliberto, 1993                | 51        | DIP‡        | 80        | 9.8         | D, MI, CHF | 26.2                     | 0           | ...    |
| Lewis, 1997                    | 52        | DSE‡        | 63        | 8           | D, MI, CHF | 28.6                     | 3.6         | ...    |

Annualized Event Rate indicates the percentage of patients per year who developed at least 1 adverse event during follow-up, depending on whether inducible ischemia was or was not demonstrated by stress echocardiography (the annualized event rate is also tabulated for those series describing patients who had normal resting and normal stress results); Stress, stress echocardiography protocol; Total Pts, number of patients studied with stress echocardiography and subsequently followed up for the development of adverse events (including death, nonfatal myocardial infarction, revascularization, or unstable angina; in posttransplant patients, development of severe congestive heart failure was also considered an adverse event); Avg F/U, average period of follow-up after stress echocardiography; DIP, dipyridamole stress echocardiography; D, death; MI, nonfatal myocardial infarction; NL, series describing follow-up only in subjects with normal stress echocardiography test results; TME, treadmill stress echocardiography; DSE, dobutamine stress echocardiography; UA, unstable angina; Re, revascularization necessary; w, patients in these series were all women; and CHF, development of severe congestive heart failure.

\*Prognostic value of inducible ischemia, detected with different forms of stress echocardiography, in patients with chronic ischemic heart disease and patients after cardiac transplantation.

†New wall motion abnormality considered "positive" for inducible ischemia.

‡Any wall motion abnormality (at rest or with stress) considered "positive."

**TABLE 3. Prognostic Value of Viable (Hibernating) Myocardium by LD-DSE and Influence of Revascularization**

| First Author, Year | Ref. | Stress | Total Pts | Avg F/U, mo | Adverse Events | Annualized Event Rate, % |             |            |
|--------------------|------|--------|-----------|-------------|----------------|--------------------------|-------------|------------|
|                    |      |        |           |             |                | Viable, +Re              | Viable, -Re | Not Viable |
| Meluzin, 1998      | 53   | LD-DSE | 133       | 20          | Death, MI      | 4.1                      | ...         | 9.5        |
| Afridi, 1998       | 54   | LD-DSE | 353       | 18          | Death          | 4                        | 20          | 19         |

LD-DSE indicates low-dose dobutamine stress echocardiography; Ref., reference number; Stress, stress echocardiography protocol; Total Pts, number of patients with chronic ischemic heart disease and impaired left ventricular systolic function studied with LD-DSE and subsequently followed up for the development of an adverse event (death or nonfatal myocardial infarction); Avg F/U, average period of follow-up after LD-DSE; Annualized Event Rate, percentage of patients per year who developed an adverse event during follow-up after LD-DSE; Viable, +Re, patients with viability (contractile reserve) demonstrated by LD-DSE who underwent revascularization and were then followed up; Viable, -Re, patients with viability (contractile reserve) demonstrated by LD-DSE who did not undergo revascularization and were then followed up; Not Viable, patients without contractile reserve by LD-DSE who were followed up for adverse events; and MI, nonfatal myocardial infarction.

Prognostic value of contractile reserve detected with LD-DSE in patients with chronic ischemic heart disease and impaired left ventricular systolic function. The annualized rate of death or MI is tabulated in patients with viable myocardium by LD-DSE depending on whether they did or did not undergo revascularization and also in those patients without viable myocardium.

**TABLE 4. Diagnostic Accuracy of Exercise Echocardiography in Detecting Angiographically Proved CAD (Without Correction for Referral Bias)**

| First Author, Year | Ref. | Exercise   | Significant CAD              | Total Pts | Sensitivity, % | Sens 1-VD, % | Sens MVD, % | Specificity, % | PPV, % | NPV, % | Accuracy, % |
|--------------------|------|------------|------------------------------|-----------|----------------|--------------|-------------|----------------|--------|--------|-------------|
| Limacher, 1983     | 55   | TME        | Greater than 50%             | 73        | 91             | 64           | 98          | 88             | 96     | 75     | 90          |
| Armstrong, 1986    | 56   | TME        | Greater than or equal to 50% | 95        | 88             | ...          | ...         | 87             | 97     | 57     | 87          |
| Armstrong, 1987    | 57   | TME        | Greater than or equal to 50% | 123       | 88             | 81           | 93          | 86             | 97     | 61     | 88          |
| Ryan, 1988         | 58   | TME        | Greater than or equal to 50% | 64        | 78             | 76           | 80          | 100            | 100    | 73     | 86          |
| Labovitz, 1989     | 59   | TME        | Greater than or equal to 70% | 56        | 76             | ...          | ...         | 100            | 100    | 74     | 86          |
| Sawada, 1989       | 60   | TME or UBE | Greater than or equal to 50% | 57        | 86             | 88           | 82          | 86             | 86     | 86     | 86          |
| Sheikh, 1990       | 61   | TME        | Greater than or equal to 50% | 34        | 74             | 74           | ...         | 91             | 94     | 63     | 79          |
| Pozzoli, 1991      | 62   | UBE        | Greater than or equal to 50% | 75        | 71             | 61           | 94          | 96             | 97     | 64     | 80          |
| Crouse, 1991       | 63   | TME        | Greater than or equal to 50% | 228       | 97             | 92           | 100         | 64             | 90     | 87     | 89          |
| Galanti, 1991      | 64   | UBE        | Greater than or equal to 70% | 53        | 93             | 93           | 92          | 96             | 96     | 93     | 94          |
| Marwick, 1992      | 65   | TME        | Greater than or equal to 50% | 150       | 84             | 79           | 96          | 86             | 95     | 63     | 85          |
| Quinones, 1992     | 66   | TME        | Greater than or equal to 50% | 112       | 74             | 59           | 89          | 88             | 96     | 51     | 78          |
| Salustri, 1992     | 67   | BE         | Greater than or equal to 50% | 44        | 87             | 87           | ...         | 85             | 93     | 75     | 86          |
| Amanullah, 1992    | 68   | UBE        | Greater than or equal to 50% | 27        | 82             | ...          | ...         | 80             | 95     | 50     | 81          |
| Hecht, 1993        | 69   | SBE        | Greater than or equal to 50% | 180       | 93             | 84           | 100         | 86             | 95     | 79     | 91          |
| Ryan, 1993         | 70   | UBE        | Greater than or equal to 50% | 309       | 91             | 86           | 95          | 78             | 90     | 81     | 87          |
| Mertes, 1993       | 71   | SBE        | Greater than or equal to 50% | 79        | 84             | 87           | 89          | 85             | 91     | 75     | 85          |
| Hoffmann, 1993     | 72   | SBE        | Greater than 70%             | 66        | 80             | 79           | 81          | 88             | 95     | 58     | 82          |
| Cohen, 1993        | 73   | SBE        | Greater than 70%             | 52        | 78             | 63           | 90          | 87             | 94     | 62     | 81          |
| Marwick, 1994      | 74   | BE         | Greater than 50%             | 86        | 88             | 82           | 91          | 80             | 89     | 77     | 85          |
| Roger, 1994        | 75   | TME        | Greater than or equal to 50% | 150       | 91             | ...          | ...         | ...            | ...    | ...    | ...         |
| Marangelli, 1994   | 76   | TME        | Greater than or equal to 75% | 80        | 89             | 76           | 97          | 91             | 93     | 86     | 90          |
| Beleslin, 1994     | 77   | TME        | Greater than or equal to 50% | 136       | 88             | 88           | 91          | 82             | 97     | 50     | 88          |
| Williams, 1994     | 78   | UBE        | Greater than 50%             | 70        | 88             | 89           | 86          | 84             | 83     | 89     | 86          |
| Roger, 1995        | 79   | TME        | Greater than or equal to 50% | 127       | 88             | ...          | ...         | 72             | 93     | 60     | ...         |
| Dagianti, 1995     | 80   | SBE        | Greater than 70%             | 60        | 76             | 70           | 80          | 94             | 90     | 85     | 87          |
| Marwick, 1995      | 81   | TME or UBE | Greater than or equal to 50% | 161       | 80             | 75           | 85          | 81             | 71     | 91     | 81          |
| Bjornstad, 1995    | 82   | UBE        | Greater than or equal to 50% | 37        | 84             | 78           | 86          | 67             | 93     | 44     | 81          |
| Marwick, 1995      | 83   | TME        | Greater than 50%             | 147       | 71             | 63           | 80          | 91             | 85     | 81     | 82          |
| Tawa, 1996         | 84   | TME        | Greater than 70%             | 45        | 94             | ...          | ...         | 83             | 94     | 83     | 91          |
| Luotolahti, 1996   | 85   | UBE        | Greater than or equal to 50% | 118       | 94             | 94           | 93          | 70             | 97     | 50     | 92          |
| Tian, 1996         | 86   | TME        | Greater than 50%             | 46        | 88             | 91           | 86          | 93             | 97     | 76     | 89          |
| Roger, 1997        | 87   | TME        | Greater than or equal to 50% | 340       | 78             | ...          | ...         | 41             | 79     | 40     | 69          |

CAD indicates coronary artery disease; Ref., reference number; Exercise, type of exercise testing used in conjunction with transthoracic echocardiographic imaging; Significant CAD, % coronary luminal diameter narrowing, demonstrated by selective coronary angiography, considered to represent significant CAD; Total Pts, number of patients in each series undergoing selective coronary angiography in whom exercise echocardiographic studies and wall motion analysis were also performed; Sens 1-VD, test results positive in patients with single-vessel CAD; Sens MVD, test results positive in patients with multivessel disease; PPV, positive predictive value (likelihood of angiographically significant CAD in patients with inducible wall motion abnormalities by exercise echocardiography); NPV, negative predictive value (likelihood of absence of angiographically significant CAD in patients without inducible wall motion abnormalities by exercise echocardiography); TME, treadmill exercise; UBE, upright bicycle ergometry; BE, bicycle ergometry; and SBE, supine bicycle ergometry.

A new or worsening regional wall motion abnormality induced by stress generally was considered a "positive" result.

### Section XIII. Echocardiography in the Critically Ill

#### Recommendations for Echocardiography in the Critically Ill

Comment: This section has been revised extensively. A discussion has been added on the echocardiographic detection of pulmonary embolism and the usefulness of TEE versus TTE in the critically ill patient. A section on the value of echocardiography in blunt aortic trauma has also been added.

The evidence tables have been extensively revised and updated.<sup>139–164</sup>

#### Class III

1. Suspected myocardial contusion in the hemodynamically stable patient with a normal ECG **who has no abnormal cardiac/thoracic physical findings and/or lacks a mechanism of injury that suggests cardiovascular contusion.**

**TABLE 5. Diagnostic Accuracy of Dobutamine Stress Echocardiography in Detecting Angiographically Proved CAD (Without Correction for Referral Bias)**

| Author, Year        | Ref. | Protocol   | Significant CAD              | Total Pts | Sensitivity, % | Sens 1-VD, % | Sens MVD, % | Specificity, % | PPV, % | NPV, % | Accuracy, % |
|---------------------|------|------------|------------------------------|-----------|----------------|--------------|-------------|----------------|--------|--------|-------------|
| Berthe, 1986        | 88   | DSE 5–40   | Greater than or equal to 50% | 30        | 85             | ...          | 85          | 88             | 85     | 88     | 87          |
| Sawada, 1991        | 89   | DSE 2.5–30 | Greater than or equal to 50% | 55        | 89             | 81           | 100         | 85             | 91     | 81     | 74          |
| Sawada, 1991        | 89   | DSE 2.5–30 | Greater than or equal to 50% | 41        | 81             | ...          | 81          | 87             | 91     | 72     | 87          |
| Previtali, 1991     | 90   | DSE 5–40   | Greater than or equal to 70% | 35        | 68             | 50           | 92          | 100            | 100    | 44     | 83          |
| Cohen, 1991         | 91   | DSE 2.5–40 | Greater than 70%             | 70        | 86             | 69           | 94          | 95             | 98     | 72     | 89          |
| Martin, 1992        | 92   | DSE 10–40  | Greater than 50%             | 34        | 76             | ...          | ...         | 44             | 79     | 40     | 68          |
| McNeill, 1992       | 93   | DASE 10–40 | Greater than or equal to 50% | 28        | 71             | ...          | ...         | ...            | ...    | ...    | 71          |
| Segar, 1992         | 94   | DSE 5–30   | Greater than or equal to 50% | 88        | 95             | ...          | ...         | 82             | 94     | 86     | 92          |
| Mazeika, 1992       | 95   | DSE 5–20   | Greater than or equal to 70% | 50        | 78             | 50           | 92          | 93             | 97     | 62     | 82          |
| Marcovitz, 1992     | 96   | DSE 5–30   | Greater than or equal to 50% | 141       | 96             | 95           | 98          | 66             | 91     | 84     | 89          |
| McNeill, 1992       | 97   | DASE 10–40 | Greater than or equal to 50% | 80        | 70             | ...          | ...         | 88             | 89     | 67     | 78          |
| Salustri, 1992      | 98   | DSE 5–40   | Greater than or equal to 50% | 46        | 79             | ...          | ...         | 78             | 85     | 70     | 78          |
| Marwick, 1993       | 99   | DSE 5–40   | Greater than or equal to 50% | 97        | 85             | 84           | 86          | 82             | 88     | 78     | 84          |
| Forster, 1993       | 100  | DASE 10–40 | Greater than 50%             | 21        | 75             | -            | -           | 89             | 90     | 73     | 81          |
| Gunalp, 1993        | 101  | DSE 5–30   | Greater than 50%             | 27        | 83             | 78           | 89          | 89             | 94     | 73     | 85          |
| Marwick, 1993       | 102  | DSE 5–40   | Greater than or equal to 50% | 217       | 72             | 66           | 77          | 83             | 89     | 61     | 76          |
| Hoffmann, 1993      | 72   | DASE 5–40  | Greater than 70%             | 64        | 79             | 78           | 81          | 81             | 93     | 57     | 80          |
| Previtali, 1993     | 103  | DSE 5–40   | Greater than 50%             | 80        | 79             | 63           | 91          | 83             | 92     | 61     | 80          |
| Takeuchi, 1993      | 104  | DSE 5–30   | Greater than or equal to 50% | 120       | 85             | 73           | 97          | 93             | 95     | 80     | 88          |
| Cohen, 1993         | 73   | DSE 2.5–40 | Greater than 70%             | 52        | 86             | 75           | 95          | 87             | 94     | 72     | 87          |
| Ostojic, 1994       | 105  | DSE 5–40   | Greater than or equal to 50% | 150       | 75             | 74           | 81          | 79             | 96     | 31     | 75          |
| Marwick, 1994       | 74   | DSE 5–40   | Greater than 50%             | 86        | 54             | 36           | 65          | 83             | 86     | 49     | 64          |
| Beleslin, 1994      | 77   | DSE 5–40   | Greater than or equal to 50% | 136       | 82             | 82           | 82          | 76             | 96     | 38     | 82          |
| Sharp, 1994         | 106  | DSE 5–50   | Greater than or equal to 50% | 54        | 83             | 69           | 89          | 71             | 89     | 59     | 80          |
| Pellikka, 1995      | 107  | DSE 5–40   | Greater than or equal to 50% | 67        | 98             | ...          | ...         | 65             | 84     | 94     | 87          |
| Ho, 1995            | 108  | DSE 5–40   | Greater than or equal to 50% | 54        | 93             | 100          | 92          | 73             | 93     | 73     | 89          |
| Daoud, 1995         | 109  | DSE 5–30   | Greater than or equal to 50% | 76        | 92             | 91           | 93          | 73             | 95     | 62     | 89          |
| Dagianti, 1995      | 80   | DSE 5–40   | Greater than or equal to 70% | 60        | 72             | 60           | 80          | 97             | 95     | 83     | 87          |
| Pingitore, 1996     | 110  | DASE 5–40  | Greater than or equal to 50% | 110       | 84             | 78           | 88          | 89             | 97     | 52     | 85          |
| Schroder, 1996      | 111  | DASE 10–40 | Greater than or equal to 50% | 46        | 76             | 71           | 90          | 88             | 97     | 44     | 78          |
| Anthopoulos, 1996   | 44   | DASE 5–40  | Greater than or equal to 50% | 120       | 87             | 74           | 90          | 84             | 94     | 68     | 86          |
| Ling, 1996          | 112  | DASE 5–40  | Greater than or equal to 50% | 183       | 93             | ...          | ...         | 62             | 95     | 54     | 90          |
| Takeuchi, 1996      | 113  | DASE 5–40  | Greater than or equal to 50% | 70        | 75             | 78           | 73          | 92             | 79     | 90     | 87          |
| Minardi, 1997       | 114  | DASE 5–40  | Greater than or equal to 50% | 47        | 75             | 81           | 67          | 67             | 97     | 15     | 74          |
| Dionisopoulos, 1997 | 115  | DASE 5–40  | Greater than or equal to 50% | 288       | 87             | 80           | 91          | 89             | 95     | 71     | 87          |
| Elhendy, 1997       | 116  | DASE 5–40  | Greater than or equal to 50% | 306       | 74             | 59           | 83          | 85             | 94     | 50     | 76          |
| Ho, 1998            | 117  | DSE 5–40   | Greater than or equal to 50% | 51        | 93             | 89           | 95          | 82             | 87     | 90     | 88          |

CAD indicates coronary artery disease; Ref., reference number; Protocol, dobutamine stress protocol, including initial and peak infusion rates (expressed in micrograms per kilogram per minute); Significant CAD, % coronary luminal diameter narrowing, demonstrated by selective coronary angiography, considered to represent significant CAD; Total Pts, number of patients in each series undergoing selective coronary angiography in whom dobutamine stress echocardiographic studies and wall motion analysis were also performed; Sens 1-VD, test results positive in patients with single-vessel CAD; Sens MVD, test results positive in patients with multivessel CAD; PPV, positive predictive value (likelihood of angiographically significant CAD in patients with inducible wall motion abnormalities by pharmacological stress echocardiography); NPV, negative predictive value (likelihood of absence of angiographically significant CAD in patients without inducible wall motion abnormalities by pharmacological stress echocardiography); DSE, dobutamine stress echocardiography; and DASE, dobutamine/atropine stress echocardiography.

A new or worsening regional wall motion abnormality induced by stress generally was considered a "positive" result.

**TABLE 6. Diagnostic Accuracy of Stress Echocardiography in Detecting Angiographically Proved CAD in Women (Generally Without Correction for Referral Bias)**

| First Author, Year                   | Ref. | Protocol   | Significant CAD              | Total Pts | Sensitivity, % | Sens 1-VD, % | Sens MVD, %        | Specificity, % | PPV, % | NPV, % | Accuracy, % |
|--------------------------------------|------|------------|------------------------------|-----------|----------------|--------------|--------------------|----------------|--------|--------|-------------|
| Masini, 1988                         | 118  | DIP        | Greater than or equal to 70% | 83        | 79             | ...          | ...                | 93             | 91     | 84     | 87          |
| Sawada, 1989                         | 60   | TME or UBE | Greater than or equal to 50% | 57        | 86             | 88           | 82                 | 86             | 86     | 86     | 86          |
| Severi, 1994                         | 119  | DIP        | Greater than or equal to 75% | 122       | 68             | ...          | ...                | 96             | 90     | 86     | 87          |
| Williams, 1994                       | 78   | UBE        | Greater than 50%             | 70        | 88             | 89           | 86                 | 84             | 83     | 89     | 86          |
| Marwick, 1995                        | 81   | TME or UBE | Greater than or equal to 50% | 161       | 80             | 75           | 85                 | 81             | 71     | 87     | 81          |
| Takeuchi, 1996                       | 113  | DASE       | Greater than or equal to 50% | 70        | 75             | 78           | 73                 | 92             | 79     | 90     | 87          |
| Roger, 1997                          | 87   | TME or UBE | Greater than or equal to 50% | 96        | 79             | ...          | ...                | 37             | 66     | 54     | 63          |
| Dionisopoulos, 1997                  | 115  | DASE       | Greater than or equal to 50% | 101       | 90             | 79           | 94                 | 79             | 90     | 79     | 86          |
| Laurienzo, 1997                      | 120  | DS-TEE     | Greater than or equal to 70% | 84        | 82             | ...          | ...                | 100            | 100    | 94     | 95          |
| Elhendy, 1997                        | 116  | DASE       | Greater than or equal to 50% | 96        | 76             | 64           | 92                 | 94             | 96     | 68     | 82          |
| Ho, 1998                             | 117  | DSE        | Greater than or equal to 50% | 51        | 93             | 89           | 95                 | 82             | 87     | 90     | 88          |
| Studies accounting for referral bias |      |            |                              |           |                |              |                    |                |        |        |             |
| Lewis, 1999 (by design)              | 121  | DSE        | Greater than or equal to 50% | 92        | 40             | 40           | 60*<br>82†         | 81             | 71     | 84     | 70          |
| Roger, 1997 (by adjustment)          | 87   | TME        | Greater than or equal to 50% | 1714      | 32             | 24           | 31 (2V)<br>43 (3V) | 86             | 66     |        |             |

CAD indicates coronary artery disease; Ref., reference number; Protocol, exercise or pharmacological protocol used in conjunction with transthoracic echocardiographic imaging; Significant CAD, % coronary luminal diameter narrowing, documented by selective coronary angiography, considered to represent significant CAD; Total Pts, number of women in each series undergoing selective coronary angiography in whom stress echocardiographic studies and wall motion analysis were also performed; Sens 1-VD, test results positive in patients with single-vessel CAD; Sens MVD, test results positive in patients with multivessel CAD; PPV, positive predictive value (likelihood of angiographically significant CAD in patients with inducible wall motion abnormalities by stress echocardiography); NPV, negative predictive value (likelihood of absence of angiographically significant CAD in patients without inducible wall motion abnormalities by stress echocardiography); DIP, dipyridamole stress echocardiography; TME, treadmill stress echocardiography; UBE, upright bicycle stress echocardiography; DASE, dobutamine/atropine stress echocardiography; DS-TEE, dobutamine stress transesophageal echocardiography; and DSE, dobutamine stress echocardiography.

A new or worsening regional wall motion abnormality induced by stress generally was considered a "positive" result.

\*Including all patients.

†Excluding patients with indeterminate studies.

## Section XIV. Two-Dimensional Echocardiography in the Adult Patient With Congenital Heart Disease

### Recommendations for Echocardiography in the Adult Patient With Congenital Heart Disease

Comment: A section has been added on the accuracy of echocardiography to allow surgery to proceed without catheterization in some congenital heart lesions. Echocardiography is useful in the performance of interventional therapeutic procedures.<sup>165-177</sup>

#### Class I

- Patients with known congenital heart disease in whom it is important that pulmonary artery pressure be monitored (eg, patients with **hemodynamically important, moderate, or large** ventricular septal defects, atrial septal defects, single ventricle, or any of the above with an additional risk factor for pulmonary hypertension).
- Periodic echocardiography in patients with repaired (or palliated) congenital heart disease with the following: change in clinical condition or clinical suspicion of residual defects, **obstruction of conduits and baffles**, or LV or RV function that must be monitored, or when there is a possibility of hemodynamic progression or a history of pulmonary hypertension.

- Identification of site of origin and initial course of coronary arteries (TEE may be indicated in some patients).\*

\*TEE may be necessary to image both coronary origins in adults.

## Section XV-E. Acquired Cardiovascular Disease in the Neonate

### Recommendations for Neonatal Echocardiography

Comment: Only minor changes have been made in this section. Two new Class I recommendations and one Class III recommendation have been added.<sup>177-194</sup> One recommendation has moved from Class IIb to Class IIa. Class I recommendations have been renumbered for clarity.

#### Class I

- Re-evaluation after initiation or termination of medical therapy for pulmonary artery hypertension.
- Re-evaluation during initiation or withdrawal of extracorporeal cardiopulmonary support.

#### Class IIa

- Presence of a syndrome associated with a high incidence of congenital heart disease for which there are no abnormal cardiac findings and no urgency of management decisions.

### Class IIb

1. Moved to Class IIa (see above).

### Class III

2. **Acrocyanosis with normal upper- and lower-extremity pulsed oximetry oxygen saturations.**

## Section XV-F. Congenital Cardiovascular Disease in the Infant, Child, and Adolescent

### Recommendations for Echocardiography in the Infant, Child, and Adolescent

Comment: There are two new Class I recommendations, which have been renumbered for clarity.<sup>6,195–200</sup>

#### Class I

5. Selection, placement, patency, and monitoring of endovascular devices, as well as identification of intracardiac or intravascular shunting before, during, and subsequent to interventional cardiac catheterization.
6. Immediate assessment after percutaneous interventional cardiac catheterization procedure.
10. Presence of a syndrome associated with cardiovascular disease and dominant inheritance or multiple affected family members (eg, **Marfan syndrome or Ehlers-Danlos syndrome**).

Deleted:

Phenotypic findings of Marfan syndrome or Ehlers-Danlos syndrome.

Presence of a syndrome associated with high incidence of congenital heart disease when there are no abnormal cardiac findings.

“Atypical,” “nonvasodepressor” syncope without other causes.

## Section XV-G. Arrhythmias/Conduction Disturbances

### Recommendations for Echocardiography in Pediatric Patients With Arrhythmias/Conduction Disturbances

Comment: Echocardiography is discretionary after radiofrequency catheter ablation. Persistent ventricular dilatation after successful ablation or effective medical control of the heart rate may indicate an arrhythmogenic primary cardiomyopathy.<sup>201–203</sup>

#### Class IIa

2. Evidence of pre-excitation on ECG **with symptoms**.

#### Class IIb

3. Examination **immediately after radiofrequency ablation**.

## Section XV-H. Acquired Cardiovascular Disease

### Recommendations for Echocardiography in Pediatric Acquired Cardiovascular Disease

Comment: The leading cause of death after the first posttransplant year is transplant-related CAD. There is evidence that stress echocardiography identifies subclinical ischemia.<sup>204–213</sup>

#### Class I

3. Baseline and re-evaluation examinations of patients receiving cardiotoxic **chemotherapeutic agents**.
5. Patients with severe renal disease and/or **systemic hypertension**.

#### Class III

1. **Routine screening echocardiogram for participation in competitive sports in patients with normal cardiovascular examination.**

## Section XV-I. Pediatric Acquired Cardiopulmonary Disease

### Recommendations for Echocardiography in Pediatric Acquired Cardiopulmonary Disease

Comment: Echocardiography provides documentation of pulmonary artery hypertension and estimation of severity by the presence of RV dilation and/or hypertrophy, the presence of tricuspid or pulmonic valvular regurgitation, and Doppler estimation of RV systolic pressure.<sup>214,215</sup>

#### Class I

2. **Re-evaluation after surgical intervention or initiation of oral and/or parenteral vasodilator therapy for pulmonary artery hypertension.**
3. **Re-evaluation during withdrawal of extracorporeal cardiopulmonary support.**

## Section XV-K. Transesophageal Echocardiography

### Recommendations for TEE in Pediatric Patients

Comment: TEE has become particularly helpful in guiding placement of catheter-deployed devices used in closing atrial septal defects. It is essential in ensuring proper positioning of the device in the defect and assessing for residual shunts and abnormal device occlusion of venous inflow into the atria or encroachment on the atrioventricular valves. Likewise, placement of catheters for radiofrequency ablation of arrhythmogenic pathways can be facilitated by TEE when there are intracardiac abnormalities.<sup>216–222</sup>

#### Class I

2. Monitoring and guidance during cardiothoracic **surgical procedures**.
8. **Patients with right atrial to pulmonary artery Fontan connection, for identification of atrial thrombus.**

#### Class IIa

1. **Patients with lateral tunnel Fontan palliation.**

## Section XVI. Intraoperative Echocardiography

### Recommendations for Intraoperative Echocardiography

Comment: This section is new. In 1996, a task force of the American Society of Anesthesiologists/Society of Cardiovascular Anesthesiologists (ASA/SCA) published practice guidelines for perioperative TEE. The guidelines were evidence based and focused on the effectiveness of perioperative TEE in improving clinical outcomes. A literature search conducted at that time retrieved 1844 articles, of which 588 were considered relevant to the perioperative setting. A more recent literature search identified an additional 118 articles related to the intraoperative use of echocardiography. The current text makes reference only to the latter. However, the indications for intraoperative echocardiography that are provided in these guidelines are based on both the initial ASA/SCA guidelines and the newer information.<sup>223–260</sup>

For a detailed discussion of this topic, please see the full-text version of the guidelines posted on the ACC, AHA, and American Society of Echocardiography (ASE) World Wide Web sites.

#### Class I

1. Evaluation of acute, persistent, and life-threatening hemodynamic disturbances in which ventricular function and its determinants are uncertain and have not responded to treatment.
2. Surgical repair of valvular lesions, hypertrophic obstructive cardiomyopathy, and aortic dissection with possible aortic valve involvement.
3. Evaluation of complex valve replacements requiring homografts or coronary reimplantation, such as the Ross procedure.
4. Surgical repair of most congenital heart lesions that require cardiopulmonary bypass.
5. Surgical intervention for endocarditis when preoperative testing was inadequate or extension to perivalvular tissue is suspected.
6. Placement of intracardiac devices and monitoring of their position during port-access and other cardiac surgical interventions.
7. Evaluation of pericardial window procedures in patients with posterior or loculated pericardial effusions.

#### Class IIa

1. Surgical procedures in patients at increased risk of myocardial ischemia, myocardial infarction, or hemodynamic disturbances.
2. Evaluation of valve replacement, aortic atheromatous disease, the Maze procedure, cardiac aneurysm repair, removal of cardiac tumors, intracardiac thrombectomy, and pulmonary embolectomy.
3. Detection of air emboli during cardiectomy, heart transplant operations, and upright neurosurgical procedures.

#### Class IIb

1. Evaluation of suspected cardiac trauma, repair of acute thoracic aortic dissection without valvular

involvement, and anastomotic sites during heart and/or lung transplantation.

2. Evaluation of regional myocardial function during and after off-pump coronary artery bypass graft procedures.
3. Evaluation of pericardiectomy, pericardial effusions, and pericardial surgery.
4. Evaluation of myocardial perfusion, coronary anatomy, or graft patency.
5. Dobutamine stress testing to detect inducible demand ischemia or to predict functional changes after myocardial revascularization.
6. Assessment of residual duct flow after interruption of patent ductus arteriosus.

#### Class III

1. Surgical repair of uncomplicated secundum atrial septal defect.

### References

1. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). *J Am Coll Cardiol*. 2001;37:2215–2239.
2. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS): a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2001;37:1478–1492.
3. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Available at: [http://www.acc.org/clinical/guidelines/perio/update/periupdate\\_index.htm](http://www.acc.org/clinical/guidelines/perio/update/periupdate_index.htm). Accessed June 12, 2002.
4. Sutherland GR, Stewart MJ, Groundstroem KW, et al. Color Doppler myocardial imaging: a new technique for the assessment of myocardial function. *J Am Soc Echocardiogr*. 1994;7:441–458.
5. Isaza K. Pulsed Doppler tissue imaging. *Am J Cardiol*. 1998;81:663. Letter.
6. Bonow RO, Carabello BA, Chaitlin MD. American College of Cardiology/American Heart Association practice guidelines for the management of patients with valvular heart disease. *J Am Coll Cardiol*. 1998;32:1486–1588.
7. Jick H. Heart valve disorders and appetite-suppressant drugs. *JAMA*. 2000;283:1738–1740. Editorial.
8. Corti R, Binggeli C, Turina M, et al. Predictors of long-term survival after valve replacement for chronic aortic regurgitation: is M-mode echocardiography sufficient? *Eur Heart J*. 2001;22:866–873.
9. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. *JAMA*. 2000;283:1703–1709.
10. Flemming MA, Oral H, Rothman ED, et al. Echocardiographic markers for mitral valve surgery to preserve left ventricular performance in mitral regurgitation. *Am Heart J*. 2000;140:476–482.
11. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. *Am J Med*. 1994;96:200–209.
12. Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated *Staphylococcus aureus* bacteremia. *Ann Intern Med*. 1999;130:810–820.
13. Marzullo P, Parodi O, Reichenhofer B, et al. Value of rest thallium-201/technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. *Am J Cardiol*. 1993;71:166–172.

14. Cigarroa CG, deFilippi CR, Brickner ME, et al. Dobutamine stress echocardiography identifies hibernating myocardium and predicts recovery of left ventricular function after coronary revascularization. *Circulation*. 1993;88:430–436.
15. Alfieri O, La Canna G, Giubbini R, et al. Recovery of myocardial function: the ultimate target of coronary revascularization. *Eur J Cardiothorac Surg*. 1993;7:325–330.
16. La Canna G, Alfieri O, Giubbini R, et al. Echocardiography during infusion of dobutamine for identification of reversibly dysfunction in patients with chronic coronary artery disease. *J Am Coll Cardiol*. 1994; 23:617–626.
17. Charney R, Schwinger ME, Chun J, et al. Dobutamine echocardiography and resting-redistribution thallium-201 scintigraphy predicts recovery of hibernating myocardium after coronary revascularization. *Am Heart J*. 1994;128:864–869.
18. Afridi I, Kleiman NS, Raizner AE, et al. Dobutamine echocardiography in myocardial hibernation: optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. *Circulation*. 1995;91:663–670.
19. Perrone-Filardi P, Pace L, Prastaro M, et al. Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascularization in patients with coronary artery disease. *Circulation*. 1995;91:2556–2565.
20. Senior R, Glenville B, Basu S, et al. Dobutamine echocardiography and thallium-201 imaging predict functional improvement after revascularization in severe ischaemic left ventricular dysfunction. *Br Heart J*. 1995;74:358–364.
21. Haque T, Furukawa T, Takahashi M, et al. Identification of hibernating myocardium by dobutamine stress echocardiography: comparison with thallium-201 reinjection imaging. *Am Heart J*. 1995;130:553–563.
22. Arnesen M, Cornel JH, Salustri A, et al. Prediction of improvement of regional left ventricular function after surgical revascularization: a comparison of low-dose dobutamine echocardiography with <sup>201</sup>Tl single-photon emission computed tomography. *Circulation*. 1995;91: 2748–2752.
23. deFilippi CR, Willett DL, Irani WN, et al. Comparison of myocardial contrast echocardiography and low-dose dobutamine stress echocardiography in predicting recovery of left ventricular function after coronary revascularization in chronic ischemic heart disease. *Circulation*. 1995; 92:2863–2868.
24. Iliceto S, Galiuto L, Marchese A, et al. Analysis of microvascular integrity, contractile reserve, and myocardial viability after acute myocardial infarction by dobutamine echocardiography and myocardial contrast echocardiography. *Am J Cardiol*. 1996;77:441–445.
25. Varga A, Ostojic M, Djordjevic-Dikic A, et al. Infra-low dose dipyridamole test: a novel dose regimen for selective assessment of myocardial viability by vasodilator stress echocardiography. *Eur Heart J*. 1996;17:629–634.
26. Baer FM, Voth E, Deutsch HJ, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. *J Am Coll Cardiol*. 1996;28:60–69.
27. Vanoverschelde JL, D'Hondt AM, Marwick T, et al. Head-to-head comparison of exercise-redistribution-reinjection thallium single-photon emission computed tomography and low dose dobutamine echocardiography for prediction of reversibility of chronic left ventricular ischemic dysfunction. *J Am Coll Cardiol*. 1996;28:432–442.
28. Gerber BL, Vanoverschelde JL, Bol A, et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: implications for the pathophysiology of chronic myocardial hibernation. *Circulation*. 1996;94:651–659.
29. Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction after revascularization: comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. *J Am Coll Cardiol*. 1996;28:558–564.
30. Perrone-Filardi P, Pace L, Prastaro M, et al. Assessment of myocardial viability in patients with chronic coronary artery disease: rest-4-hour-24-hour <sup>201</sup>Tl tomography versus dobutamine echocardiography. *Circulation*. 1996;94:2712–2719.
31. Qureshi U, Nagueh SF, Afridi I, et al. Dobutamine echocardiography and quantitative rest-redistribution <sup>201</sup>Tl tomography in myocardial hibernation: relation of contractile reserve to <sup>201</sup>Tl uptake and comparative prediction of recovery of function. *Circulation*. 1997;95: 626–635.
32. Nagueh SF, Vaduganathan P, Ali N, et al. Identification of hibernating myocardium: comparative accuracy of myocardial contrast echocardiography, rest-redistribution thallium-201 tomography and dobutamine echocardiography. *J Am Coll Cardiol*. 1997;29:985–993.
33. Furukawa T, Haque T, Takahashi M, et al. An assessment of dobutamine echocardiography and end-diastolic wall thickness for predicting post-revascularization functional recovery in patients with chronic coronary artery disease. *Eur Heart J*. 1997;18:798–806.
34. Cornel JH, Bax JJ, Fioretti PM, et al. Prediction of improvement of ventricular function after revascularization: <sup>18</sup>F-fluorodeoxyglucose single-photon emission computed tomography vs low-dose dobutamine echocardiography. *Eur Heart J*. 1997;18:941–948.
35. Picano E, Severi S, Michelassi C, et al. Prognostic importance of dipyridamole-echocardiography test in coronary artery disease. *Circulation*. 1989;80:450–457.
36. Sawada SG, Ryan T, Conley MJ, et al. Prognostic value of a normal exercise echocardiogram. *Am Heart J*. 1990;120:49–55.
37. Mazeika PK, Nadazdin A, Oakley CM. Prognostic value of dobutamine echocardiography in patients with high pretest likelihood of coronary artery disease. *Am J Cardiol*. 1993;71:33–39.
38. Krivokapich J, Child JS, Gerber RS, et al. Prognostic usefulness of positive or negative exercise stress echocardiography for predicting coronary events in ensuing twelve months. *Am J Cardiol*. 1993;71: 646–651.
39. Afridi I, Quinones MA, Zoghbi WA, et al. Dobutamine stress echocardiography: sensitivity, specificity, and predictive value for future cardiac events. *Am Heart J*. 1994;127:1510–1515.
40. Poldermans D, Fioretti PM, Boersma E, et al. Dobutamine-atropine stress echocardiography and clinical data for predicting late cardiac events in patients with suspected coronary artery disease. *Am J Med*. 1994;97:119–125.
41. Coletta C, Galati A, Greco G, et al. Prognostic value of high dose dipyridamole echocardiography in patients with chronic coronary artery disease and preserved left ventricular function. *J Am Coll Cardiol*. 1995;26:887–894.
42. Karaman M, Teague SM, Finkelhor RS, et al. Prognostic value of dobutamine stress echocardiography in patients referred because of suspected coronary artery disease. *Am J Cardiol*. 1995;76:887–891.
43. Williams MJ, Odabashian J, Lauer MS, et al. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. *J Am Coll Cardiol*. 1996;27:132–139.
44. Anthopoulos LP, Bonou MS, Kardaras FG, et al. Stress echocardiography in elderly patients with coronary artery disease: applicability, safety and prognostic value of dobutamine and adenosine echocardiography in elderly patients. *J Am Coll Cardiol*. 1996;28:52–59.
45. Marcovitz PA, Shayna V, Horn RA, et al. Value of dobutamine stress echocardiography in determining the prognosis of patients with known or suspected coronary artery disease. *Am J Cardiol*. 1996;78:404–408.
46. Heupler S, Mehta R, Lobo A, et al. Prognostic implications of exercise echocardiography in women with known or suspected coronary artery disease. *J Am Coll Cardiol*. 1997;30:414–420.
47. McCully RB, Roger VL, Mahoney DW, et al. Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients. *J Am Coll Cardiol*. 1998;31:144–149.
48. Chuah SC, Pellikka PA, Roger VL, et al. Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease. *Circulation*. 1998;97:1474–1480.
49. Cortigiani L, Dodi C, Paolini EA, et al. Prognostic value of pharmacological stress echocardiography in women with chest pain and unknown coronary artery disease. *J Am Coll Cardiol*. 1998;32:1975–1981.
50. Davar JJ, Brull DJ, Bulughipitiya S, et al. Prognostic value of negative dobutamine stress echo in women with intermediate probability of coronary artery disease. *Am J Cardiol*. 1999;83:100–102, A8.
51. Ciliberto GR, Massa D, Mangiacavalli M, et al. High-dose dipyridamole echocardiography test in coronary artery disease after heart transplantation. *Eur Heart J*. 1993;14:48–52.
52. Lewis JF, Selman SB, Murphy JD, et al. Dobutamine echocardiography for prediction of ischemic events in heart transplant recipients. *J Heart Lung Transplant*. 1997;16:390–393.
53. Meluzin J, Cerny J, Frelich M, et al, on behalf of the Investigators of this Multicenter Study. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery

- disease and left ventricular dysfunction. *J Am Coll Cardiol*. 1998;32:912–920.
54. Afridi I, Grayburn PA, Panza JA, et al. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. *J Am Coll Cardiol*. 1998;32:921–926.
  55. Limacher MC, Quinones MA, Poliner LR, et al. Detection of coronary artery disease with exercise two-dimensional echocardiography: description of a clinically applicable method and comparison with radionuclide ventriculography. *Circulation*. 1983;67:1211–1218.
  56. Armstrong WF, O'Donnell J, Dillon JC, et al. Complementary value of two-dimensional exercise echocardiography to routine treadmill exercise testing. *Ann Intern Med*. 1986;105:829–835.
  57. Armstrong WF, O'Donnell J, Ryan T, et al. Effect of prior myocardial infarction and extent and location of coronary disease on accuracy of exercise echocardiography. *J Am Coll Cardiol*. 1987;10:531–538.
  58. Ryan T, Vasey CG, Presti CF, et al. Exercise echocardiography: detection of coronary artery disease in patients with normal left ventricular wall motion at rest. *J Am Coll Cardiol*. 1988;11:993–999.
  59. Labovitz AJ, Lewen M, Kern MJ, et al. The effects of successful PTCA on left ventricular function: assessment by exercise echocardiography. *Am Heart J*. 1989;117:1003–1008.
  60. Sawada SG, Ryan T, Fineberg NS, et al. Exercise echocardiographic detection of coronary artery disease in women. *J Am Coll Cardiol*. 1989;14:1440–1447.
  61. Sheikh KH, Bengtson JR, Helmy S, et al. Relation of quantitative coronary lesion measurements to the development of exercise-induced ischemia assessed by exercise echocardiography. *J Am Coll Cardiol*. 1990;15:1043–1051.
  62. Pozzoli MM, Fioretti PM, Salustri A, et al. Exercise echocardiography and technetium-99m MIBI single-photon emission computed tomography in the detection of coronary artery disease. *Am J Cardiol*. 1991;67:350–355.
  63. Crouse LJ, Harbrecht JJ, Vacek JL, et al. Exercise echocardiography as a screening test for coronary artery disease and correlation with coronary arteriography. *Am J Cardiol*. 1991;67:1213–1218.
  64. Galanti G, Sciagra R, Comeglio M, et al. Diagnostic accuracy of peak exercise echocardiography in coronary artery disease: comparison with thallium-201 myocardial scintigraphy. *Am Heart J*. 1991;122:1609–1616.
  65. Marwick TH, Nemec JJ, Pashkow FJ, et al. Accuracy and limitations of exercise echocardiography in a routine clinical setting. *J Am Coll Cardiol*. 1992;19:74–81.
  66. Quinones MA, Verani MS, Haichin RM, et al. Exercise echocardiography versus <sup>201</sup>Tl single-photon emission computed tomography in evaluation of coronary artery disease: analysis of 292 patients. *Circulation*. 1992;85:1026–1031.
  67. Salustri A, Pozzoli MM, Hermans W, et al. Relationship between exercise echocardiography and perfusion single-photon emission computed tomography in patients with single-vessel coronary artery disease. *Am Heart J*. 1992;124:75–83.
  68. Amanullah AM, Lindvall K, Bevegard S. Exercise echocardiography after stabilization of unstable angina: correlation with exercise thallium-201 single photon emission computed tomography. *Clin Cardiol*. 1992;15:585–589.
  69. Hecht HS, DeBord L, Shaw R, et al. Digital supine bicycle stress echocardiography: a new technique for evaluating coronary artery disease. *J Am Coll Cardiol*. 1993;21:950–956.
  70. Ryan T, Segar DS, Sawada SG, et al. Detection of coronary artery disease with upright bicycle exercise echocardiography. *J Am Soc Echocardiogr*. 1993;6:186–197.
  71. Mertes H, Erbel R, Nixdorff U, et al. Exercise echocardiography for the evaluation of patients after nonsurgical coronary artery revascularization. *J Am Coll Cardiol*. 1993;21:1087–1093.
  72. Hoffmann R, Lethen H, Kleinhans E, et al. Comparative evaluation of bicycle and dobutamine stress echocardiography with perfusion scintigraphy and bicycle electrocardiogram for identification of coronary artery disease. *Am J Cardiol*. 1993;72:555–559.
  73. Cohen JL, Ottenweller JE, George AK, et al. Comparison of dobutamine and exercise echocardiography for detecting coronary artery disease. *Am J Cardiol*. 1993;72:1226–1231.
  74. Marwick TH, D'Hondt AM, Mairesse GH, et al. Comparative ability of dobutamine and exercise stress in inducing myocardial ischemia in active patients [published erratum appears in *Br Heart J*. 1994;72:590]. *Br Heart J*. 1994;72:31–38.
  75. Roger VL, Pellikka PA, Oh JK, et al. Identification of multivessel coronary artery disease by exercise echocardiography. *J Am Coll Cardiol*. 1994;24:109–114.
  76. Marangelli V, Illiceto S, Piccinni G, et al. Detection of coronary artery disease by digital stress echocardiography: comparison of exercise, transthoracic atrial pacing and dipyridamole echocardiography. *J Am Coll Cardiol*. 1994;24:117–124.
  77. Beleslin BD, Ostojic M, Stepanovic J, et al. Stress echocardiography in the detection of myocardial ischemia: head-to-head comparison of exercise, dobutamine, and dipyridamole tests. *Circulation*. 1994;90:1168–1176.
  78. Williams MJ, Marwick TH, O'Gorman D, et al. Comparison of exercise echocardiography with an exercise score to diagnose coronary artery disease in women. *Am J Cardiol*. 1994;74:435–438.
  79. Roger VL, Pellikka PA, Oh JK, et al. Stress echocardiography, part I: exercise echocardiography: techniques, implementation, clinical applications, and correlations. *Mayo Clin Proc*. 1995;70:5–15.
  80. Dagianti A, Penco M, Agati L, et al. Stress echocardiography: comparison of exercise, dipyridamole and dobutamine in detecting and predicting the extent of coronary artery disease [published erratum appears in *J Am Coll Cardiol*. 1995;26:1114]. *J Am Coll Cardiol*. 1995;26:18–25.
  81. Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women. *J Am Coll Cardiol*. 1995;26:335–341.
  82. Bjornstad K, Aakhus S, Hatle L. Comparison of digital dipyridamole stress echocardiography and upright bicycle stress echocardiography for identification of coronary artery stenosis. *Cardiology*. 1995;86:514–520.
  83. Marwick TH, Torelli J, Harjai K, et al. Influence of left ventricular hypertrophy on detection of coronary artery disease using exercise echocardiography. *J Am Coll Cardiol*. 1995;26:1180–1186.
  84. Tawa CB, Baker WB, Kleiman NS, et al. Comparison of adenosine echocardiography, with and without isometric handgrip, to exercise echocardiography in the detection of ischemia in patients with coronary artery disease. *J Am Soc Echocardiogr*. 1996;9:33–43.
  85. Luotolahti M, Saraste M, Hartiala J. Exercise echocardiography in the diagnosis of coronary artery disease. *Ann Med*. 1996;28:73–77.
  86. Tian J, Zhang G, Wang X, et al. Exercise echocardiography: feasibility and value for detection of coronary artery disease. *Chin Med J (Engl)*. 1996;109:381–384.
  87. Roger VL, Pellikka PA, Bell MR, et al. Sex and test verification bias: impact on the diagnostic value of exercise echocardiography. *Circulation*. 1997;95:405–410.
  88. Berthe C, Pierard LA, Hiernaux M, et al. Predicting the extent and location of coronary artery disease in acute myocardial infarction by echocardiography during dobutamine infusion. *Am J Cardiol*. 1986;58:1167–1172.
  89. Sawada SG, Segar DS, Ryan T, et al. Echocardiographic detection of coronary artery disease during dobutamine infusion. *Circulation*. 1991;83:1605–1614.
  90. Previtali M, Lanzarini L, Ferrario M, et al. Dobutamine versus dipyridamole echocardiography in coronary artery disease. *Circulation*. 1991;83:III-27–III-31.
  91. Cohen JL, Greene TO, Ottenweller J, et al. Dobutamine digital echocardiography for detecting coronary artery disease. *Am J Cardiol*. 1991;67:1311–1318.
  92. Martin TW, Seaworth JF, Johns JP, et al. Comparison of adenosine, dipyridamole, and dobutamine in stress echocardiography. *Ann Intern Med*. 1992;116:190–196.
  93. McNeill AJ, Fioretti PM, el Said SM, et al. Dobutamine stress echocardiography before and after coronary angioplasty. *Am J Cardiol*. 1992;69:740–745.
  94. Segar DS, Brown SE, Sawada SG, et al. Dobutamine stress echocardiography: correlation with coronary lesion severity as determined by quantitative angiography. *J Am Coll Cardiol*. 1992;19:1197–1202.
  95. Mazeika PK, Nadazdin A, Oakley CM. Dobutamine stress echocardiography for detection and assessment of coronary artery disease. *J Am Coll Cardiol*. 1992;19:1203–1211.
  96. Marcovitz PA, Armstrong WF. Accuracy of dobutamine stress echocardiography in detecting coronary artery disease. *Am J Cardiol*. 1992;69:1269–1273.
  97. McNeill AJ, Fioretti PM, el Said EM, et al. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. *Am J Cardiol*. 1992;70:41–46.

98. Salustri A, Fioretti PM, McNeill AJ, et al. Pharmacological stress echocardiography in the diagnosis of coronary artery disease and myocardial ischaemia: a comparison between dobutamine and dipyridamole. *Eur Heart J*. 1992;13:1356–1362.
99. Marwick T, Willemart B, D'Hondt AM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion: comparison of dobutamine and adenosine using echocardiography and <sup>99m</sup>Tc-MIBI single photon emission computed tomography. *Circulation*. 1993;87:345–354.
100. Forster T, McNeill AJ, Salustri A, et al. Simultaneous dobutamine stress echocardiography and technetium-99m isonitrite single-photon emission computed tomography in patients with suspected coronary artery disease. *J Am Coll Cardiol*. 1993;21:1591–1596.
101. Gunalp B, Dokumaci B, Uyan C, et al. Value of dobutamine technetium-99m-sestamibi SPECT and echocardiography in the detection of coronary artery disease compared with coronary angiography. *J Nucl Med*. 1993;34:889–894.
102. Marwick T, D'Hondt AM, Baudhuin T, et al. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? *J Am Coll Cardiol*. 1993;22:159–167.
103. Previtali M, Lanzarini L, Fetiveau R, et al. Comparison of dobutamine stress echocardiography, dipyridamole stress echocardiography and exercise stress testing for diagnosis of coronary artery disease. *Am J Cardiol*. 1993;72:865–870.
104. Takeuchi M, Araki M, Nakashima Y, et al. Comparison of dobutamine stress echocardiography and stress thallium-201 single-photon emission computed tomography for detecting coronary artery disease. *J Am Soc Echocardiogr*. 1993;6:593–602.
105. Ostojic M, Picano E, Beleslin B, et al. Dipyridamole-dobutamine echocardiography: a novel test for the detection of milder forms of coronary artery disease. *J Am Coll Cardiol*. 1994;23:1115–1122.
106. Sharp SM, Sawada SG, Segar DS, et al. Dobutamine stress echocardiography: detection of coronary artery disease in patients with dilated cardiomyopathy. *J Am Coll Cardiol*. 1994;24:934–939.
107. Pellikka PA, Roger VL, Oh JK, et al. Stress echocardiography, part II: dobutamine stress echocardiography: techniques, implementation, clinical applications, and correlations. *Mayo Clin Proc*. 1995;70:16–27.
108. Ho FM, Huang PJ, Liau CS, et al. Dobutamine stress echocardiography compared with dipyridamole thallium-201 single-photon emission computed tomography in detecting coronary artery disease. *Eur Heart J*. 1995;16:570–575.
109. Daoud EG, Pitt A, Armstrong WF. Electrocardiographic response during dobutamine stress echocardiography. *Am Heart J*. 1995;129:672–677.
110. Pingitore A, Picano E, Colosso MQ, et al. The atropine factor in pharmacologic stress echocardiography: Echo Persantine (EPIC) and Echo Dobutamine International Cooperative (EDIC) Study Groups. *J Am Coll Cardiol*. 1996;27:1164–1170.
111. Schroder K, Voller H, Dingerkus H, et al. Comparison of the diagnostic potential of four echocardiographic stress tests shortly after acute myocardial infarction: submaximal exercise, transesophageal atrial pacing, dipyridamole, and dobutamine-atropine. *Am J Cardiol*. 1996;77:909–914.
112. Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. *J Am Coll Cardiol*. 1996;28:551–557.
113. Takeuchi M, Sonoda S, Miura Y, et al. Comparative diagnostic value of dobutamine stress echocardiography and stress thallium-201 single-photon-emission computed tomography for detecting coronary artery disease in women. *Coron Artery Dis*. 1996;7:831–835.
114. Minardi G, Di Segni M, Manzara CC, et al. Diagnostic and prognostic value of dipyridamole and dobutamine stress echocardiography in patients with Q-wave acute myocardial infarction. *Am J Cardiol*. 1997;80:847–851.
115. Dionisopoulos PN, Collins JD, Smart SC, et al. The value of dobutamine stress echocardiography for the detection of coronary artery disease in women. *J Am Soc Echocardiogr*. 1997;10:811–817.
116. Elhendy A, Geleijnse ML, van Domburg RT, et al. Gender differences in the accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery disease. *Am J Cardiol*. 1997;80:1414–1418.
117. Ho YL, Wu CC, Huang PJ, et al. Assessment of coronary artery disease in women by dobutamine stress echocardiography: comparison with stress thallium-201 single-photon emission computed tomography and exercise electrocardiography. *Am Heart J*. 1998;135:655–662.
118. Masini M, Picano E, Lattanzi F, et al. High dose dipyridamole-echocardiography test in women: correlation with exercise-electrocardiography test and coronary arteriography. *J Am Coll Cardiol*. 1988;12:682–685.
119. Severi S, Picano E, Michelassi C, et al. Diagnostic and prognostic value of dipyridamole echocardiography in patients with suspected coronary artery disease: comparison with exercise electrocardiography. *Circulation*. 1994;89:1160–1173.
120. Laurienzo JM, Cannon RO III, Quyyumi AA, et al. Improved specificity of transesophageal dobutamine stress echocardiography compared to standard tests for evaluation of coronary artery disease in women presenting with chest pain. *Am J Cardiol*. 1997;80:1402–1407.
121. Lewis JF, Lin L, McGorray S, et al. Dobutamine stress echocardiography in women with chest pain: pilot phase data from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). *J Am Coll Cardiol*. 1999;33:1462–1468.
122. Wittlich N, Erbel R, Eichler A, et al. Detection of central pulmonary artery thromboemboli by transesophageal echocardiography in patients with severe pulmonary embolism. *J Am Soc Echocardiogr*. 1992;5:515–524.
123. Saxon LA, Stevenson WG, Fonarow GC, et al. Transesophageal echocardiography during radiofrequency catheter ablation of ventricular tachycardia. *Am J Cardiol*. 1993;72:658–661.
124. Tucker KJ, Curtis AB, Murphy J, et al. Transesophageal echocardiographic guidance of transeptal left heart catheterization during radiofrequency ablation of left-sided accessory pathways in humans. *Pacing Clin Electrophysiol*. 1996;19:272–281.
125. Chu E, Kalman JM, Kwasman MA, et al. Intracardiac echocardiography during radiofrequency catheter ablation of cardiac arrhythmias in humans. *J Am Coll Cardiol*. 1994;24:1351–1357.
126. Fisher WG, Pelini MA, Bacon ME. Adjunctive intracardiac echocardiography to guide slow pathway ablation in human atrioventricular nodal reentrant tachycardia: anatomic insights. *Circulation*. 1997;96:3021–3029.
127. Pires LA, Huang SK, Wagshal AB, et al. Clinical utility of routine transthoracic echocardiographic studies after uncomplicated radiofrequency catheter ablation: a prospective multicenter study: the Atakr Investigators Group. *Pacing Clin Electrophysiol*. 1996;19:1502–1507.
128. Cox JL, Schuessler RB, Lappas DG, et al. An 8 1/2-year clinical experience with surgery for atrial fibrillation. *Ann Surg*. 1996;224:267–273.
129. Albirini A, Scalia GM, Murray RD, et al. Left and right atrial transport function after the Maze procedure for atrial fibrillation: an echocardiographic Doppler follow-up study. *J Am Soc Echocardiogr*. 1997;10:937–945.
130. Charron P, Dubourg O, Desnos M, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. *Circulation*. 1997;96:214–219.
131. Grunig E, Tasman JA, Kucherer H, et al. Frequency and phenotypes of familial dilated cardiomyopathy. *J Am Coll Cardiol*. 1998;31:186–194.
132. Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity: Heart Muscle Disease Study Group. *J Am Coll Cardiol*. 1999;34:181–190.
133. Baig MK, Goldman JH, Caforio AL, et al. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. *J Am Coll Cardiol*. 1998;31:195–201.
134. Crispell KA, Wray A, Ni H, et al. Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: preliminary recommendations for clinical practice. *J Am Coll Cardiol*. 1999;34:837–847.
135. Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry: Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. *Circulation*. 2000;101:E101–E106.
136. Coonar AS, Protonotarios N, Tsatsopoulou A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. *Circulation*. 1998;97:2049–2058.
137. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome: a statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular

- Disease in the Young, and Basic Science, American Heart Association. *Circulation*. 1998;98:1460–1471.
138. Fuller CM. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. *Med Sci Sports Exerc*. 2000; 32:887–890.
  139. Alam M. Transesophageal echocardiography in critical care units: Henry Ford Hospital experience and review of the literature. *Prog Cardiovasc Dis*. 1996;38:315–328.
  140. Brandt RR, Oh JK, Abel MD, et al. Role of emergency intraoperative transesophageal echocardiography. *J Am Soc Echocardiogr*. 1998;11: 972–977.
  141. Chan D. Echocardiography in thoracic trauma. *Emerg Med Clin North Am*. 1998;16:191–207.
  142. Cicek S, Demirlic U, Kuralay E, et al. Transesophageal echocardiography in cardiac surgical emergencies. *J Card Surg*. 1995;10:236–244.
  143. Gendreau MA, Triner WR, Bartfield J. Complications of transesophageal echocardiography in the ED. *Am J Emerg Med*. 1999;17:248–251.
  144. Kornbluth M, Liang DH, Brown P, et al. Contrast echocardiography is superior to tissue harmonics for assessment of left ventricular function in mechanically ventilated patients. *Am Heart J*. 2000;140:291–296.
  145. Miller RL, Das S, Anandarangam T, et al. Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism. *Chest*. 1998;113: 665–670.
  146. Perrier A, Howarth N, Didier D, et al. Performance of helical computed tomography in unselected outpatients with suspected pulmonary embolism. *Ann Intern Med*. 2001;135:88–97.
  147. Pretre R, Chilcott M. Blunt trauma to the heart and great vessels. *N Engl J Med*. 1997;336:626–632.
  148. Pruszczyk P, Torbicki A, Pacho R, et al. Noninvasive diagnosis of suspected severe pulmonary embolism: transesophageal echocardiography vs spiral CT. *Chest*. 1997;112:722–728.
  149. Reilly JP, Tunick PA, Timmermans RJ, et al. Contrast echocardiography clarifies uninterpretable wall motion in intensive care unit patients. *J Am Coll Cardiol*. 2000;35:485–490.
  150. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. *Am Heart J*. 1997;134:479–487.
  151. Ritchie ME, Srivastava BK. Use of transesophageal echocardiography to detect unsuspected massive pulmonary emboli. *J Am Soc Echocardiogr*. 1998;11:751–754.
  152. Shanewise JS, Cheung AT, Aronson S, et al. ASE/SCA guidelines for performing a comprehensive intraoperative multiplane transesophageal echocardiography examination: recommendations of the American Society of Echocardiography Council for Intraoperative Echocardiography and the Society of Cardiovascular Anesthesiologists Task Force for Certification in Perioperative Transesophageal Echocardiography. *J Am Soc Echocardiogr*. 1999;12:884–900.
  153. Slama MA, Novara A, Van de Putte P, et al. Diagnostic and therapeutic implications of transesophageal echocardiography in medical ICU patients with unexplained shock, hypoxemia, or suspected endocarditis. *Intensive Care Med*. 1996;22:916–922.
  154. Tam JW, Nichol J, MacDiarmid AL, et al. What is the real clinical utility of echocardiography? A prospective observational study. *J Am Soc Echocardiogr*. 1999;12:689–697.
  155. Tousignant C. Transesophageal echocardiographic assessment in trauma and critical care. *Can J Surg*. 1999;42:171–175.
  156. Ben Menachem Y. Assessment of blunt aortic-brachiocephalic trauma: should angiography be supplanted by transesophageal echocardiography? *J Trauma*. 1997;42:969–972.
  157. Fabian TC, Richardson JD, Croce MA, et al. Prospective study of blunt aortic injury: Multicenter Trial of the American Association for the Surgery of Trauma. *J Trauma*. 1997;42:374–380.
  158. Mirvis SE, Shanmuganathan K, Buell J, et al. Use of spiral computed tomography for the assessment of blunt trauma patients with potential aortic injury. *J Trauma*. 1998;45:922–930.
  159. Patel NH, Stephens KE Jr, Mirvis SE, et al. Imaging of acute thoracic aortic injury due to blunt trauma: a review. *Radiology*. 1998;209: 335–348.
  160. Poelaert J, Schmidt C, Van Aken H, et al. Transoesophageal echocardiography in critically ill patients: a comprehensive approach. *Eur J Anaesthesiol*. 1997;14:350–358.
  161. Smith MD, Cassidy JM, Souter S, et al. Transesophageal echocardiography in the diagnosis of traumatic rupture of the aorta. *N Engl J Med*. 1995;332:356–362.
  162. Stewart WJ, Douglas PS, Sagar K, et al. Echocardiography in emergency medicine: a policy statement by the American Society of Echocardiography and the American College of Cardiology: The Task Force on Echocardiography in Emergency Medicine of the American Society of Echocardiography and the Echocardiography TPEC Committees of the American College of Cardiology. *J Am Soc Echocardiogr*. 1999;12:82–84.
  163. Vignon P, Gueret P, Vedrinne JM, et al. Role of transesophageal echocardiography in the diagnosis and management of traumatic aortic disruption. *Circulation*. 1995;92:2959–2968.
  164. Vignon P, Lagrange P, Boncoeur MP, et al. Routine transesophageal echocardiography for the diagnosis of aortic disruption in trauma patients without enlarged mediastinum. *J Trauma*. 1996;40:422–427.
  165. Bartel T, Muller S, Erbel R. Dynamic three-dimensional echocardiography using parallel slicing: a promising diagnostic procedure in adults with congenital heart disease. *Cardiology*. 1998;89:140–147.
  166. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults: second of two parts [published erratum appears in *N Engl J Med*. 2000;342:988]. *N Engl J Med*. 2000;342:334–342.
  167. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults: first of two parts. *N Engl J Med*. 2000;342:256–263.
  168. Harrison DA, McLaughlin PR. Interventional cardiology for the adult patient with congenital heart disease: the Toronto Hospital experience. *Can J Cardiol*. 1996;12:965–971.
  169. Hartnell GG, Cohen MC, Meier RA, et al. Magnetic resonance angiography demonstration of congenital heart disease in adults. *Clin Radiol*. 1996;51:851–857.
  170. Hoppe UC, Dederichs B, Deutsch HJ, et al. Congenital heart disease in adults and adolescents: comparative value of transthoracic and transesophageal echocardiography and MR imaging. *Radiology*. 1996;199: 669–677.
  171. Li J, Sanders SP. Three-dimensional echocardiography in congenital heart disease. *Curr Opin Cardiol*. 1999;14:53–59.
  172. Marelli AJ, Child JS, Perloff JK. Transesophageal echocardiography in congenital heart disease in the adult. *Cardiol Clin*. 1993;11:505–520.
  173. Pfammatter JP, Berdat P, Hammerli M, et al. Pediatric cardiac surgery after exclusively echocardiography-based diagnostic work-up. *Int J Cardiol*. 2000;74:185–190.
  174. Simpson IA, Sahn DJ. Adult congenital heart disease: use of transthoracic echocardiography versus magnetic resonance imaging scanning. *Am J Card Imaging*. 1995;9:29–37.
  175. Sreeram N, Sutherland GR, Geuskens R, et al. The role of transoesophageal echocardiography in adolescents and adults with congenital heart defects. *Eur Heart J*. 1991;12:231–240.
  176. Triedman JK, Bergau DM, Saul JP, et al. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease. *J Am Coll Cardiol*. 1997;30:1032–1038.
  177. Tworetzky W, McElhinney DB, Brook MM, et al. Echocardiographic diagnosis alone for the complete repair of major congenital heart defects. *J Am Coll Cardiol*. 1999;33:228–233.
  178. Fritz KI, Bhat AM. Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. *J Perinatol*. 1998;18: 38–44.
  179. Garcia JA, Zellers TM, Weinstein EM, et al. Usefulness of Doppler echocardiography in diagnosing right ventricular coronary arterial communications in patients with pulmonary atresia and intact ventricular septum and comparison with angiography. *Am J Cardiol*. 1998;81: 103–104.
  180. Jureidini SB, Marino CJ, Singh GK, et al. Main coronary artery and coronary ostial stenosis in children: detection by transthoracic color flow and pulsed Doppler echocardiography. *J Am Soc Echocardiogr*. 2000; 13:255–263.
  181. Kovalchin JP, Brook MM, Rosenthal GL, et al. Echocardiographic hemodynamic and morphometric predictors of survival after two-ventricle repair in infants with critical aortic stenosis [published erratum appears in *J Am Coll Cardiol*. 1999;33:591]. *J Am Coll Cardiol*. 1998; 32:237–244.
  182. Krauser DG, Rutkowski M, Phoon CK. Left ventricular volume after correction of isolated aortic coarctation in neonates. *Am J Cardiol*. 2000;85:904–907, A10.
  183. Magee AG, Boutin C, McCrindle BW, et al. Echocardiography and cardiac catheterization in the preoperative assessment of ventricular septal defect in infancy. *Am Heart J*. 1998;135:907–913.

184. Martin GR, Short BL, Abbott C, et al. Cardiac stun in infants undergoing extracorporeal membrane oxygenation. *J Thorac Cardiovasc Surg.* 1991;101:607–611.
185. McCrindle BW, Shaffer KM, Kan JS, et al. An evaluation of parental concerns and misperceptions about heart murmurs. *Clin Pediatr (Phila).* 1995;34:25–31.
186. Pfammatter JP, Berdat PA, Carrel TP, et al. Pediatric open heart operations without diagnostic cardiac catheterization. *Ann Thorac Surg.* 1999;68:532–536.
187. Rychik J, Jacobs ML, Norwood WI. Early changes in ventricular geometry and ventricular septal defect size following Rastelli operation or intraventricular baffle repair for conotruncal anomaly: a cause for development of subaortic stenosis. *Circulation.* 1994;90:II-13–II-19.
188. Salzer-Muhar U, Marx M, Ties M, et al. Doppler flow profiles in the right and left pulmonary artery in children with congenital heart disease and a bidirectional cavopulmonary shunt. *Pediatr Cardiol.* 1994;15:302–307.
189. Schulze-Neick I, Bultmann M, Werner H, et al. Right ventricular function in patients treated with inhaled nitric oxide after cardiac surgery for congenital heart disease in newborns and children. *Am J Cardiol.* 1997;80:360–363.
190. Sreeram N, Colli AM, Monro JL, et al. Changing role of non-invasive investigation in the preoperative assessment of congenital heart disease: a nine year experience. *Br Heart J.* 1990;63:345–349.
191. Suda K, Bigras JL, Bohn D, et al. Echocardiographic predictors of outcome in newborns with congenital diaphragmatic hernia. *Pediatrics.* 2000;105:1106–1109.
192. Tamura M, Menahem S, Brizard C. Clinical features and management of isolated cleft mitral valve in childhood. *J Am Coll Cardiol.* 2000;35:764–770.
193. Tani LY, Minich LL, Hawkins JA, et al. Influence of left ventricular cavity size on interventricular shunt timing and outcome in neonates with coarctation of the aorta and ventricular septal defect. *Am J Cardiol.* 1999;84:750–752, A9.
194. Wren C, Richmond S, Donaldson L. Presentation of congenital heart disease in infancy: implications for routine examination. *Arch Dis Child Fetal Neonatal Ed.* 1999;80:F49–F53.
195. Attenhofer Jost CH, Turina J, Mayer K. Echocardiography in the evaluation of systolic murmurs of unknown cause. *Am J Med.* 2000;108:614–620.
196. Van Oort A, Blanc-Botden M, De Boo T, et al. The vibratory innocent heart murmur in schoolchildren: difference in auscultatory findings between school medical officers and a pediatric cardiologist. *Pediatr Cardiol.* 1994;15:282–287.
197. Gaskin PR, Owens SE, Talner NS, et al. Clinical auscultation skills in pediatric residents. *Pediatrics.* 2000;105:1184–1187.
198. Steinberger J, Moller JH, Berry JM, et al. Echocardiographic diagnosis of heart disease in apparently healthy adolescents. *Pediatrics.* 2000;105:815–818.
199. Danford DA, Martin AB, Fletcher SE, et al. Children with heart murmurs: can ventricular septal defect be diagnosed reliably without an echocardiogram? *J Am Coll Cardiol.* 1997;30:243–246.
200. Tsang TS, Barnes ME, Hayes SN, et al. Clinical and echocardiographic characteristics of significant pericardial effusions following cardiothoracic surgery and outcomes of echo-guided pericardiocentesis for management: Mayo Clinic experience, 1979–1998. *Chest.* 1999;116:322–331.
201. Calkins H, Yong P, Miller JM, et al, for the Atakr Multicenter Investigators Group. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. *Circulation.* 1999;99:262–270.
202. De Giovanni JV, Dindar A, Griffith MJ, et al. Recovery pattern of left ventricular dysfunction following radiofrequency ablation of incessant supraventricular tachycardia in infants and children. *Heart.* 1998;79:588–592.
203. Tanel RE, Walsh EP, Triedman JK, et al. Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients. *J Pediatr.* 1997;131:878–887.
204. Kimball TR, Witt SA, Daniels SR. Dobutamine stress echocardiography in the assessment of suspected myocardial ischemia in children and young adults. *Am J Cardiol.* 1997;79:380–384.
205. Noto N, Ayusawa M, Karasawa K, et al. Dobutamine stress echocardiography for detection of coronary artery stenosis in children with Kawasaki disease. *J Am Coll Cardiol.* 1996;27:1251–1256.
206. Pahl E, Sehgal R, Chrystof D, et al. Feasibility of exercise stress echocardiography for the follow-up of children with coronary involvement secondary to Kawasaki disease. *Circulation.* 1995;91:122–128.
207. Minich LL, Tani LY, Pagotto LT, et al. Doppler echocardiography distinguishes between physiologic and pathologic “silent” mitral regurgitation in patients with rheumatic fever. *Clin Cardiol.* 1997;20:924–926.
208. Lipshultz SE, Easley KA, Orav EJ, et al. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. *Circulation.* 1998;97:1246–1256.
209. De Wolf D, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. *Pediatr Res.* 1996;39:504–512.
210. Ichida F, Hamamichi Y, Miyawaki T, et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background. *J Am Coll Cardiol.* 1999;34:233–240.
211. Kimball TR, Witt SA, Daniels SR, et al. Frequency and significance of left ventricular thickening in transplanted hearts in children. *Am J Cardiol.* 1996;77:77–80.
212. Larsen RL, Applegate PM, Dyar DA, et al. Dobutamine stress echocardiography for assessing coronary artery disease after transplantation in children. *J Am Coll Cardiol.* 1998;32:515–520.
213. Pahl E, Crawford SE, Swenson JM, et al. Dobutamine stress echocardiography: experience in pediatric heart transplant recipients. *J Heart Lung Transplant.* 1999;18:725–732.
214. Jacobs IN, Teague WG, Bland JWJ. Pulmonary vascular complications of chronic airway obstruction in children. *Arch Otolaryngol Head Neck Surg.* 1997;123:700–704.
215. Subhedar NV, Shaw NJ. Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide. *Arch Dis Child Fetal Neonatal Ed.* 1997;77:F191–F197.
216. Chaliki HP, Click RL, Abel MD. Comparison of intraoperative transesophageal echocardiographic examinations with the operative findings: prospective review of 1918 cases. *J Am Soc Echocardiogr.* 1999;12:237–240.
217. Drant SE, Klitzner TS, Shannon KM, et al. Guidance of radiofrequency catheter ablation by transesophageal echocardiography in children with palliated single ventricle. *Am J Cardiol.* 1995;76:1311–1312.
218. Fyfe DA, Eklund CH, Sade RM, et al. Transesophageal echocardiography detects thrombus formation not identified by transthoracic echocardiography after the Fontan operation. *J Am Coll Cardiol.* 1991;18:1733–1737.
219. Podnar T, Martanovic P, Gavora P, et al. Morphological variations of secundum-type atrial septal defects: feasibility for percutaneous closure using Amplatzer septal occluders. *Catheter Cardiovasc Interv.* 2001;53:386–391.
220. Shiota T, Lewandowski R, Piel JE, et al. Micromultiplane transesophageal echocardiographic probe for intraoperative study of congenital heart disease repair in neonates, infants, children, and adults. *Am J Cardiol.* 1999;83:292–295, A7.
221. Siwik ES, Spector ML, Patel CR, et al. Costs and cost-effectiveness of routine transesophageal echocardiography in congenital heart surgery. *Am Heart J.* 1999;138:771–776.
222. Stevenson JG, Sorensen GK, Gartman DM, et al. Transesophageal echocardiography during repair of congenital cardiac defects: identification of residual problems necessitating reoperation. *J Am Soc Echocardiogr.* 1993;6:356–365.
223. Practice guidelines for perioperative transesophageal echocardiography: a report by the American Society of Anesthesiologists and the Society of Cardiovascular Anesthesiologists Task Force on Transesophageal Echocardiography. *Anesthesiology.* 1996;84:986–1006.
224. Abraham TP, Warner JG Jr, Kon ND, et al. Feasibility, accuracy, and incremental value of intraoperative three-dimensional transesophageal echocardiography in valve surgery. *Am J Cardiol.* 1997;80:1577–1582.
225. Applebaum RM, Kasliwal RR, Kanojia A, et al. Utility of three-dimensional echocardiography during balloon mitral valvuloplasty. *J Am Coll Cardiol.* 1998;32:1405–1409.

226. Aronson S, Dupont F, Savage R. Changes in regional myocardial function after coronary artery bypass graft surgery are predicted by intraoperative low-dose dobutamine echocardiography. *Anesthesiology*. 2000;93:685–692.
227. Arruda AM, Dearani JA, Click RL, et al. Intraoperative application of power Doppler imaging: visualization of myocardial perfusion after anastomosis of left internal thoracic artery to left anterior descending coronary artery. *J Am Soc Echocardiogr*. 1999;12:650–654.
228. Bergquist BD, Bellows WH, Leung JM. Transesophageal echocardiography in myocardial revascularization, II: influence on intraoperative decision making. *Anesth Analg*. 1996;82:1139–1145.
229. Breburda CS, Griffin BP, Pu M, et al. Three-dimensional echocardiographic planimetry of maximal regurgitant orifice area in myxomatous mitral regurgitation: intraoperative comparison with proximal flow convergence. *J Am Coll Cardiol*. 1998;32:432–437.
230. Choudhary SK, Bhan A, Sharma R, et al. Aortic atherosclerosis and perioperative stroke in patients undergoing coronary artery bypass: role of intra-operative transesophageal echocardiography. *Int J Cardiol*. 1997;61:31–38.
231. Click RL, Abel MD, Schaff HV. Intraoperative transesophageal echocardiography: 5-year prospective review of impact on surgical management. *Mayo Clin Proc*. 2000;75:241–247.
232. Couture P, Denault AY, McKenty S, et al. Impact of routine use of intraoperative transesophageal echocardiography during cardiac surgery. *Can J Anaesth*. 2000;47:20–26.
233. De Simone R, Glombitza G, Vahl CF, et al. Three-dimensional color Doppler for assessing mitral regurgitation during valvuloplasty. *Eur J Cardiothorac Surg*. 1999;15:127–133.
234. Falk V, Walther T, Diegeler A, et al. Echocardiographic monitoring of minimally invasive mitral valve surgery using an endoaortic clamp. *J Heart Valve Dis*. 1996;5:630–637.
235. Greene MA, Alexander JA, Knauf DG, et al. Endoscopic evaluation of the esophagus in infants and children immediately following intraoperative use of transesophageal echocardiography. *Chest*. 1999;116:1247–1250.
236. Hogue CW Jr, Lappas GD, Creswell LL, et al. Swallowing dysfunction after cardiac operations: associated adverse outcomes and risk factors including intraoperative transesophageal echocardiography. *J Thorac Cardiovasc Surg*. 1995;110:517–522.
237. Kallmeyer IJ, Collard CD, Fox JA, et al. The safety of intraoperative transesophageal echocardiography: a case series of 7200 cardiac surgical patients. *Anesth Analg*. 2001;92:1126–1130.
238. Kawano H, Mizoguchi T, Aoyagi S. Intraoperative transesophageal echocardiography for evaluation of mitral valve repair. *J Heart Valve Dis*. 1999;8:287–293.
239. Lavoie J, Javorski JJ, Donahue K, et al. Detection of residual flow by transesophageal echocardiography during video-assisted thoracoscopic patent ductus arteriosus interruption. *Anesth Analg*. 1995;80:1071–1075.
240. Lee HR, Montenegro LM, Nicolson SC, et al. Usefulness of intraoperative transesophageal echocardiography in predicting the degree of mitral regurgitation secondary to atrioventricular defect in children. *Am J Cardiol*. 1999;83:750–753.
241. Leung MP, Chau KT, Chiu C, et al. Intraoperative TEE assessment of ventricular septal defect with aortic regurgitation. *Ann Thorac Surg*. 1996;61:854–860.
242. Michel-Cherqui M, Ceddaha A, Liu N, et al. Assessment of systematic use of intraoperative transesophageal echocardiography during cardiac surgery in adults: a prospective study of 203 patients. *J Cardiothorac Vasc Anesth*. 2000;14:45–50.
243. Mishra M, Chauhan R, Sharma KK, et al. Real-time intraoperative transesophageal echocardiography: how useful? Experience of 5,016 cases. *J Cardiothorac Vasc Anesth*. 1998;12:625–632.
244. Moises VA, Mesquita CB, Campos O, et al. Importance of intraoperative transesophageal echocardiography during coronary artery surgery without cardiopulmonary bypass. *J Am Soc Echocardiogr*. 1998;11:1139–1144.
245. Morehead AJ, Firstenberg MS, Shiota T, et al. Intraoperative echocardiographic detection of regurgitant jets after valve replacement. *Ann Thorac Surg*. 2000;69:135–139.
246. Rosenfeld HM, Gentles TL, Wernovsky G, et al. Utility of intraoperative transesophageal echocardiography in the assessment of residual cardiac defects. *Pediatr Cardiol*. 1998;19:346–351.
247. Rousou JA, Tighe DA, Garb JL, et al. Risk of dysphagia after transesophageal echocardiography during cardiac operations. *Ann Thorac Surg*. 2000;69:486–489.
248. Saiki Y, Kasegawa H, Kawase M, et al. Intraoperative TEE during mitral valve repair: does it predict early and late postoperative mitral valve dysfunction? *Ann Thorac Surg*. 1998;66:1277–1281.
249. Savage RM, Lytle BW, Aronson S, et al. Intraoperative echocardiography is indicated in high-risk coronary artery bypass grafting. *Ann Thorac Surg*. 1997;64:368–373.
250. Secknus MA, Asher CR, Scalia GM, et al. Intraoperative transesophageal echocardiography in minimally invasive cardiac valve surgery. *J Am Soc Echocardiogr*. 1999;12:231–236.
251. Seeberger MD, Skarvan K, Buser P, et al. Dobutamine stress echocardiography to detect inducible demand ischemia in anesthetized patients with coronary artery disease. *Anesthesiology*. 1998;88:1233–1239.
252. Shankar S, Sreeram N, Brawn WJ, et al. Intraoperative ultrasonographic troubleshooting after the arterial switch operation. *Ann Thorac Surg*. 1997;63:445–448.
253. Sheil ML, Baines DB. Intraoperative transoesophageal echocardiography for pediatric cardiac surgery: an audit of 200 cases. *Anaesth Intensive Care*. 1999;27:591–595.
254. Stevenson JG. Role of intraoperative transesophageal echocardiography during repair of congenital cardiac defects. *Acta Paediatr Suppl*. 1995;410:23–33.
255. Sutton DC, Kluger R. Intraoperative transoesophageal echocardiography: impact on adult cardiac surgery. *Anaesth Intensive Care*. 1998;26:287–293.
256. Sylivris S, Calafiore P, Matalanis G, et al. The intraoperative assessment of ascending aortic atheroma: epiaortic imaging is superior to both transesophageal echocardiography and direct palpation. *J Cardiothorac Vasc Anesth*. 1997;11:704–707.
257. Tingleff J, Joyce FS, Pettersson G. Intraoperative echocardiographic study of air embolism during cardiac operations. *Ann Thorac Surg*. 1995;60:673–677.
258. Ungerleider RM, Kisslo JA, Greeley WJ, et al. Intraoperative echocardiography during congenital heart operations: experience from 1,000 cases. *Ann Thorac Surg*. 1995;60:S539–S542.
259. Vogel M, Ho SY, Lincoln C, et al. Three-dimensional echocardiography can simulate intraoperative visualization of congenitally malformed hearts. *Ann Thorac Surg*. 1995;60:1282–1288.
260. Yao FS, Barbut D, Hager DN, et al. Detection of aortic emboli by transesophageal echocardiography during coronary artery bypass surgery. *J Cardiothorac Vasc Anesth*. 1996;10:314–317.

---

KEY WORDS: ACC/AHA Guidelines ■ echocardiography ■ imaging